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 ABSTRACT 
Matthew Robert DiStasi 
Major Collateral Vessels Develop from Pre-existing Small Arteries  
Through Rac2/Nox2 Independent Mechanisms. 
 
There is no consensus on which vascular segment or what size of vessels is most 
important in the process of collateral growth, the degree to which these vessels can 
enlarge, or the mechanisms that mediate collateral vessel expansion and its impairment.  
Chapter I identifies the major collateral vessels that develop in response to femoral 
arterial occlusion in the pig, rat, and mouse hindlimbs for comparison to humans.  Pre-
existent small named arteries enlarged ~2-3-fold to become the major collateral vessels in 
each species, these major collaterals displayed characteristics similar to large arteries 
experiencing flow-mediated outward remodeling, and important differences in vascular 
wall thickness were observed between rodents and pigs.  Chapter II utilized Rac2-/- and 
Nox2-/- mice to investigate the hypothesis that Nox2-NAD(P)H oxidase is required for 
major collateral growth subsequent to femoral arterial occlusion.  Previous studies 
suggest bone marrow cell (BMC)-derived reactive oxygen species (ROS) produced by 
the Nox2 subunit of NAD(P)H oxidase plays an important role in neovascularization and 
recovery of hindlimb perfusion subsequent to femoral arterial occlusion; but did not 
investigate collateral growth.  The hematopoietic cell restricted protein Rac2 has been 
shown to bind to and activate Nox2-NAD(P)H oxidase and Rac2-/- and Nox2-/- 
leukocytes display impaired ROS related functions.  The data demonstrated that Rac2 and 
Nox2 are not essential for major collateral growth, but both are important for the 
 iv
 recovery of hindlimb perfusion and preservation of distal tissue morphology.  Chapter III 
investigated BMC and antioxidant therapy in the age-related impairment of collateral 
growth.  Aging, like all cardiovascular disease risk factors is associated with elevated 
ROS and impaired collateral growth.  Studies also suggest BMCs promote collateral 
growth by secreting paracrine factors but elevated ROS may affect the efficacy of BMCs.  
The data revealed that neither BMC injection nor antioxidant therapy via apocynin 
enhanced the process of major collateral artery growth in aged mice. 
 
      Joseph L. Unthank, PhD, Chair 
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 INTRODUCTION 
While great strides in the fight against cardiovascular disease (CVD) have been 
made in recent years, as indicated by the ~25% decline in CVD associated death rate 
from 1994-2004, Americans are still dying from CVD at a rate of 1 death every 37 
seconds (~2400 per day) (110).  Peripheral arterial disease (PAD) - a component of CVD 
resulting from arterial occlusion in the extremities - is known to affect ~8 million 
Americans (110) and is associated with significant morbidity and mortality (110).  One of 
the endogenous compensation mechanisms for arterial occlusion is the enlargement of 
blood vessels which bypass the site of occlusion, a process known as collateral growth.  
However, effective pharmacotherapy specifically designed to increase limb perfusion in 
PAD patients is not currently available (159).  Molecular therapies utilizing growth 
factors designed to increase hindlimb perfusion via promoting generalized vascular 
growth showed considerable promise in pre-clinical animal models; however, results 
from molecular therapy-based clinical trials have been mixed at best (153).  In addition, 
subsequent studies suggest many of these growth factor therapies were more readily able 
to modulate capillary vascular growth rather than collateral vascular growth.  While there 
are numerous potential explanations for the mediocre clinical results observed, two 
possibilities include: 1) that the pre-clinical models being used may not be an optimal 
representation of the human condition and 2) that previous studies have suggested 
capillaries are not the major determinant of hindlimb perfusion after arterial occlusion 
(46, 62, 76, 112, 121, 150, 159, 163).  Unfortunately, it appears that clinical results with 
cell-based therapies will be similar to those seen with the molecular therapies (74).  Thus, 
the fundamental question remains (which will serve as the major theme for this 
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 introduction): do the current pre-clinical rodent models adequately reflect the clinical, 
human situation?  To adequately answer this question, this introductory chapter will: 1) 
review PAD, 2) discuss the endogenous mechanisms used by the body to combat arterial 
occlusion, 3) critique some of the current animal models and analytical methods used to 
study PAD, 4) suggest whether compensation via capillary angiogenesis or collateral 
growth is more important, 5) consider the shift in emphasis from the study of collateral 
growth to angiogenesis and arteriogenesis research, 6) discuss the confusion brought on 
by the definition of arteriogenesis, and finally, 7) propose what is now needed to advance 
the field of collateral growth research. 
Review of Peripheral Arterial Disease (PAD) and its Therapeutic Interventions   
As reviewed in Greenfield’s vascular surgery textbook (by Mulholland, et al. 
2006) (88), chronic obliterative atherosclerosis of the infrainguinal vessels is the most 
prevalent manifestation of arterial occlusive disease encountered by the vascular surgeon 
and the most common lesion seen below the inguinal ligament is that of a short-segment 
total occlusion of the superficial femoral artery.  The patient populations most at risk for 
significant morbidity and mortality associated with PAD are aged patients, those with 
diabetes, and those who smoke.  PAD prevalence increases dramatically with age and 
affects 12-20% of Americans age 65 and older (110).  The risk of lower extremity PAD 
increases 2-4X in the presence of diabetes mellitus and 12-20% of patients with lower 
extremity PAD have diabetes (64).  The risk of developing lower extremity PAD 
increases 2-6X with smoking and >80% of patients with lower extremity PAD are current 
or former smokers (64).  As the occlusive process progresses, alterations in the 
hemodynamic forces within the vasculature lead to the enlargement of a network of 
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 bypass (or collateral) channels around the occluded segments (102).  The blood flow 
provided by this collateral network is usually sufficient to meet the metabolic needs of 
the lower extremities while at rest with slowly developing occlusive lesions; however, 
this network of bypass vessels cannot increase blood flow enough to meet the metabolic 
demands of exercising leg musculature (102).  The characteristic exercise-induced, 
cramping pain in the lower extremity muscles caused by chronic atherosclerotic occlusive 
disease is known as intermittent claudication (102).  When collateral pathways cannot 
meet even the basal metabolic needs of non-exercising tissue and occlusive disease in 
both the aortoiliac and infrainguinal segments is present, the outcome is pain at rest, 
tissue loss (gangrene, non-healing ulceration), and threatened limb viability – a condition 
known as critical limb ischemia (102).   
Two non-invasive methods of clinically assessing the level of disease present in 
the ischemic limb are by calculation of the ankle-brachial index and via segmental blood 
pressure measurements.  The ankle-brachial index (ABI) is a good indicator of the degree 
of ischemia present (102) and is defined as the ratio of the ankle systolic pressure to the 
brachial systolic pressure.  Normal ABIs are generally ≥1, while patients with 
claudication usually have ABIs ranging from 0.5-0.9 and patients with rest pain and 
tissue loss have ABIs of <0.5 (102).  When the arterial stenosis is not severe enough to 
cause a pressure drop while the limb is at rest, patients with claudication can occasionally 
have normal or nearly normal ABI.  However, higher rates of flow due to exercise-
induced vasodilatation in order to meet the increased metabolic demands of exercising 
muscle tissue will produce a hemodynamically observable effect (102).  In these patients, 
ABIs are measured before and after a treadmill exercise test and the sign of 
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 hemodynamically significant occlusive disease is a drop of 15% or more in the ABI 
following exercise (102).  Determination of the arterial segment involved with occlusive 
disease can be done non-invasively via segmental blood pressure measurements.  This 
method utilizes four blood pressure cuffs placed on the upper thigh, lower thigh, calf, and 
ankle.  Significant disease within the intervening arterial segment is indicated by a 
pressure drop of >20 mmHg between consecutive levels of measurement and an upper 
thigh pressure that is below normal signifies occlusive disease in the aortoiliac or 
common femoral segments (102).  Intra-arterial vasodilator injection can be used to 
mimic exercise hyperemic hemodynamics during the measurement of segmental 
pressures when the arterial stenosis is not severe enough to cause a pressure drop while 
the limb is at rest (102).   
Therapeutic intervention for PAD can range from medical stabilization of the 
symptoms through minimally or maximally invasive surgical procedures to limb 
amputation.  The selection of the most appropriate therapy is patient specific; depending 
on patient risk, surgeon experience, and the pattern of the occlusive process (102).  Due 
to the relatively stable natural history of claudication, endovascular or surgical 
intervention may or may not be needed; however, patients with critical limb ischemia 
face inevitable limb amputation unless surgical correction is performed (88).  In 
percutaneous transluminal angioplasty (PTA), a balloon catheter is inserted into the 
arterial system, guided to the point of atherosclerotic occlusion/stenosis, and then inflated 
in order to re-establish the lumen of the vessel.  PTA is best suited to the treatment of 
short, focal, non-occlusive lesions (102).  Placement of an intravascular stent to assist in 
maintaining long-term patency often supplements balloon angioplasty (41).  Iliac artery 
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 angioplasty has a 3-year patency rate of 70-90% and a 5-year rate of 50% (102); 
however, the results of PTA in the femoropopliteal system have been mixed: 43-58% 
patency at 1 year, 41-46% at 2 years, 38-41% at 3 years, and 26-38% at 5 years (41).  
Endarterectomy is limited to only good-risk patients with focal occlusive disease at the 
aortic bifurcation and common iliac arteries, is less well suited for disease extending in 
the external iliac arteries, and is to be avoided when aneurysmal degeneration 
complicates the primary atheroocclusive aortoiliac process (102).  Patients with diffuse 
atherosclerotic disease, long (>10 cm) and complex stenoses or occlusions benefit more 
from bypass/revascularization than from PTA (102).  Indeed, when medical therapy or 
percutaneous treatment has proven inadequate or is technically inadvisable, open surgical 
revascularization remains the gold standard for patients with disabling claudication, 
ischemic rest pain, and ischemic ulceration or gangrene (88).  The 5- and 10-year graft 
patency rates in aortofemoral bypass are excellent (at ~85% and 75%, respectively) and 
perioperative morbidity and mortality are reported to be below 10% and 5%, respectively 
(102).  5-year results of saphenous vein grafting to combat infrainguinal atherosclerotic 
diseases (using modern techniques) have also been excellent, with patency rates of 75-
80% and limb salvage rates as high as 90% (88).  However, despite this relative success, 
there are still patients who are not suitable candidates for revascularization, such as those 
with diffuse femoropopliteal and tibioperoneal disease, since long-distance reconstruction 
does not necessarily provide symptomatic relief and graft failure may result in distal 
arterial thrombosis and a jeopardized limb (88).  In addition, CLI is associated with a 
20% 1yr mortality rate, nearly half of patients will require revascularization for limb 
salvage, and (of those with un-reconstructable disease) ~40% will require major limb 
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 amputation within 6 months (64).  Therefore, novel therapies which could enhance 
endogenous mechanisms of increasing perfusion of the distal tissues would have 
tremendous potential for improving the morbidity and mortality caused by arterial 
occlusion within PAD. 
What are the Endogenous Mechanisms of Compensation for Arterial Occlusion? 
As previously mentioned, collateral growth is one endogenous mechanism the 
body utilizes to maintain resting tissue perfusion in the presence of arterial occlusion. 
Collateral growth is characterized by the enlargement of pre-existing bypass vessels 
which allow blood to circumvent the site of occlusion and continue to perfuse the distal 
tissues.   
Several early studies provide anatomical and functional evidence of pre-existing 
collaterals.  In 1911, Matas (84) recognized the importance of the collateral circulation 
stating “The surgery of the vascular system bristles with problems which still await 
solution, but none appear to me more important or fundamental than the study of the 
collateral circulation in its behavior to occluded arteries” and then designed a method of 
testing the efficiency of the collateral circulation in humans which he utilized to 
determine which patients were amenable to surgical aneurisms repair.  Eckstein (1941) 
(42) measured distal pressure and flow recovery after femoral, carotid, and coronary 
occlusion in the dog and demonstrated the presence of pre-existent vessels by observing 
an ~50% recovery of distal pressure within the first 90 min after occlusion; far too little a 
time for new vessels to form.  In a review on arterial injury in World War II, DeBakey 
and Simeone (1946) (37) state that “after interruption of a major artery of a limb, the 
circulation may be so seriously impaired as to necessitate amputation of the limb; or it 
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 may be entirely adequate, so that a few weeks after the injury, there may be no detectable 
abnormality”, thus suggesting the presence of pre-existent collaterals.  DeBakey and 
Simeone (37) go on to repeatedly discuss the importance of maintaining the collateral 
circulation after arterial injury.  Shepherd (1950) (125) measured calf blood flow upon 
mechanical compression of the femoral artery in humans and observed that calf blood 
flow initially dropped to ~1/6th of the resting pre-occlusion value and then recovered to 
near the resting level within an average of 2 min, again indicating the presence of pre-
existing collaterals.  Longland (1953) (81) identified pre-existing collaterals in the 
hindlimbs of rabbits and serially observed their enlargement over the course of a year.  
Rosenthal and Guiton (1968) (111) used conductance to estimate the dilation of pre-
existent collaterals within the first hour after femoral artery occlusion in the dog and 
observed a ~277% rise in conductance in the first 70 seconds following occlusion, 
demonstrating the presence of pre-existing collaterals.  Gorey et al. (1979) (51) reported 
that in 14 cases of iliac artery ligation to control hemorrhage during renal transplantation 
none of the patients lost their limbs, none of the patients required immediate iliac bypass 
surgery, and only 2 eventually required reconstruction due to symptoms of claudication, 
demonstrating the presence of pre-existent collateral vessels.  Gorey et al. (51) went on to 
list both the parietal and the visceral pre-existent named arteries which could provide 
potential collateral circulation around an occluded iliac artery.   
The evidence put forth by these and other foundational studies, in combination 
with decades of clinical observation, were compelling enough that pre-existent collaterals 
are now standard textbook knowledge (60, 92, 122, 134) for all medical students and 
have been since the publication of Gray’s Anatomy, 20th edition, in 1918 (78).  Some 
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 examples of collateral circulation readily identified in medical textbooks include: 1) the 
circle of Willis; 2) the intercostal and lumbar arteries to the circumflex iliac and 
iliolumbar arteries, the superior to inferior epigastric arteries, and the superior and 
inferior mesenteric arteries to the rectal and internal pudendal arteries, all of which are 
important collateral arterial pathways around the aortic bifurcation and common iliac 
segments; 3) the hypogastric-to-circumflex femoral channels which provide collateral 
pathways around occlusive lesions of the external iliac arteries; 4) collateral perfusion 
from the profunda femoral artery around a heavily diseased or occluded superficial 
femoral artery which frequently reconstitutes the distal superficial femoral artery or 
popliteal artery with enough well perfused arterial blood to ensure sufficient resting tissue 
perfusion (88); 5) the rich network of geniculate collaterals in the knee which can 
compensate for a diseased popliteal arterial segment to a sufficient degree to prevent rest 
pain or overt tissue loss (88, 122); and 6) collaterals between radial and ulnar arteries as 
well as between digital arteries in upper lower extremities (60).  The exact mechanism of 
collateral growth is still under investigation, but most investigators believe the initiating 
stimulus is the increased shear stress experienced by the endothelial cells of the collateral 
due to the increased flow passing through the bypass vessels upon parent artery occlusion 
(12, 45, 96, 131, 148, 154, 158). 
Another endogenous mechanism utilized by the body in an attempt to maintain 
perfusion is increasing the number of capillaries within an ischemic region, otherwise 
known as angiogenesis.  As reviewed by Simons (131), angiogenesis is stimulated by 
tissue hypoxia and proceeds via sprouting of new capillaries from post-capillary venules.  
Tissue hypoxia stimulates the expression of hypoxia-inducible factor (HIF)-1α which 
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 then activates the transcription of numerous genes, including vascular endothelial growth 
factor (VEGF) (131).  VEGF then mediates increased vascular permeability and 
endothelial cell proliferation and migration (158).  The endothelial cells migrate into the 
extracellular matrix, form tubes, and fuse to existing vessels (158).  Angiogenesis is 
known to play a role in both physiologic and pathophysiologic processes (such as 
cardiovascular disease, among others) (158) and can improve oxygen delivery to 
individual cells (80). 
A third purported endogenous process of compensating for arterial occlusion is 
vasculogenesis, or the growth of entirely new vessels (larger than capillaries) driven by 
circulating endothelial or vascular progenitor cells (131).  The benefit from 
vasculogenesis has been reported as a wide spectrum from none at all to significant (131).  
Two recent reviews suggest that it is unclear whether vasculogenesis actually occurs and 
whether vessels formed by this process are physiologically relevant (55, 57). 
Critique of the Animal Models and Analytical Methods Utilized in Recent Studies 
Major limitations of the animal models currently in use may have contributed to 
the failure of small animal models to predict clinical outcomes in the field of therapeutic 
angio-/arterio-genesis and collateral growth.  First, as reviewed by Waters (159), surgical 
ligation alone often does not result in a significant/sustainable reduction in resting blood 
flow in some animal models (14, 22, 61, 70, 123).  Waters also points out that the timing 
of perfusion assessment in animal models is critical, as these models tend to be stable 
after 1 week and, thus, it is more difficult to detect efficacy of therapy (159).  On the 
other hand, simple ligation can result in impaired blood flow capacity under stress 
conditions, such as exercise, and ligation plus excision of the femoral artery can result in 
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 reduced blood flow at rest, especially if in a diseased background (159, 161).  
Unfortunately, the more extensive the surgical ligation strategy, the more potential pre-
existing collateral pathways are eliminated and are thus unable to provide compensation.  
Thus, preclinical models which demonstrate sustained hemodynamic impairment at rest 
would roughly mimic CLI while those which demonstrate hemodynamic impairment only 
upon exercise would approximate claudication (159).   
Second, despite these rough approximations, surgically induced hindlimb 
ischemia in young healthy animals is not equivalent to human PAD.  Animal models 
primarily employ sudden ligations that usually involve only one segment and occur in a 
healthy surrounding vasculature.  In contrast, the most serious syndromes in human PAD 
usually result from gradual obstruction at multiple vascular sites and the surrounding 
vasculature contains atherosclerotic disease as well as other co-morbidities such as age, 
diabetes, hypertension, and hypercholesterolemia.  Therefore, pre-clinical models 
utilizing a single ligation to study collateral growth in the context of infrainguinal vessel 
occlusion should place their ligation on the short segment of the superficial femoral 
artery as that is known to be the most common site of occlusion in humans (88).  
However, a more accurate pre-clinical model would be one with an initially gradual 
occlusion that would eventually experience a sudden obstruction.  In addition, pre-
clinical models should utilize animals with the cardiovascular risk factor co-morbidities 
of age, diabetes, and/or smoking to most accurately mimic the human condition.  As 
models with this degree of complexity are costly and difficult to obtain, the work 
performed in the remainder of this thesis is done with either a single ligation to mimic 
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 moderate disease or a double ligation and excision of the femoral artery to mimic more 
advanced PAD and the co-morbidity of age was also investigated. 
Third, largely due to the failures of molecular therapies derived from small animal 
studies to provide clinical benefit, some investigators have suggested small animals are 
irrelevant to the human situation.  These investigators suggest that because of the size 
difference, mechanisms and/or characteristics of collateral growth, the process may be 
different in mice versus humans (this will be addressed at greater length in Chapter I).  It 
should be noted, however, that a majority of small animal studies were intended to 
investigate or enhance angiogenesis rather than collateral growth and that the molecular 
therapies derived from these studies were primarily developed in young healthy animals 
experiencing a sudden focal occlusion of their vasculature; which, as previously 
mentioned, is a very different situation from the aged patient with diffuse atherosclerotic 
disease presenting with multiple co-morbidities and experiencing gradual occlusions of 
their vasculature.  The use of mice does still have advantages, as outlined by Casal and 
Haskins (20): mice have been invaluable for the study of gene transfer methods and gene 
therapy of inherited diseases, they are relatively inexpensive, have a short generation time 
and large litters, transgenic techniques allow the development of almost any monogenetic 
disease model, and the various mouse strains are highly inbred which provides uniform 
conditions in which experiments can be easily reproduced and statistical significance 
achieved.  However, the problem of compensation by secondary mechanisms arises when 
using transgenic animals in which some portion of the primary mechanism under 
investigation has been genetically deleted.  Therefore, the failure of current molecular 
therapies which showed promise in pre-clinical animal models to translate to the clinical 
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 situation may largely be due to these limitations in the animal models utilized in those 
studies. 
In addition to limitations in the animal models utilized to study vascular 
compensation, limitations in the analytical methods used to assess vascular compensation 
are also prevalent.  For instance, few studies have specifically identified the pre-existing 
vessels which form the major or most functionally important collateral pathways and 
investigated their mechanism of enlargement.  Previous studies relied primarily on the 
following 5 methods to assess collateral development: 1) counting the number of 
angiographically visible collaterals, 2) obtaining collateral vessel density or angioscore 
(also essentially counting), 3) using micro-CT to obtain vascular volume of entire 
hindlimb, 4) using microspheres to calculate a collateral dependant flow, or 5) using laser 
Doppler perfusion imaging without ever directly assessing collateral growth.  Fuchs et al. 
(50) noted that collateral vessel density in angiograms does not correlate with collateral 
flow and angiographic scoring does not reflect tissue perfusion as assessed by 
microsphere techniques.  In addition, counting collaterals or obtaining entire hindlimb 
volume will result in the inclusion of regressing collaterals.  Regressing collaterals have 
been observed by multiple investigators (12, 63, 81, 95, 122) and are probably not a 
significant component of hindlimb perfusion, since the reason these vessels are regressing 
is due to reduced blood flow.  In addition, regressing collaterals may be undergoing an 
entirely different process than enlarging collaterals which would confound the results of 
studies aimed at investigating the mechanisms of collateral enlargement.  Using 
microspheres that are too small may cause misinterpretation of an animal’s ability to 
grow collaterals; 15 µm microspheres utilized by many studies are good for overall 
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 perfusion but not for collateral growth as they are too small, readily passing well beyond 
collaterals ranging 75-125 µm in diameter (in mice).  The most commonly used laser 
Doppler perfusion imagers cannot penetrate the tissue deeply enough to directly assess 
collateral flow, and thus, can only measure what is thought to be collateral-dependant 
flow at sites distant to the location of the actual collateral vessels.  Clinically, assessment 
of limb ischemia is performed non-invasively via segmental pressure measurements or 
obtaining the patient’s ankle-brachial index (ABI); however, these methods are seldom 
utilized in pre-clinical models of limb ischemia.  To mimic these non-invasive clinical 
assessments of ischemia, larger animal models would probably be necessary (such as 
sheep, pigs, dogs, cats, and possibly rabbits) for the segmental pressure techniques while 
animals as small as rats would probably be amenable to ABI measurement.  If 
experimental design allows invasive techniques to be performed, then either ABI or 
segmental pressure measurement can be performed in animals as small as mice (via 
catheterization of vessels proximal and distal to the occlusion); however, the 
measurement of distal pressures becomes increasingly difficult with decreasing animal 
size due to decreasing vessel size.  Therefore, the limitations of the current analytical 
techniques which do not focus on the enlarging, functionally important collaterals and 
allow for the inclusion of regressing vessels may have played a role in the inability of 
promising pre-clinical therapies to be translated into clinical outcomes.  In addition, 
incorporating analytical techniques into pre-clinical studies that more closely mimic the 
analytical techniques of the clinic may allow for a more direct comparison of therapeutic 
pre-clinical and clinical outcomes.  
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 Collateral Growth is Probably More Important in Restoring Hindlimb Perfusion after 
Arterial Occlusion than Capillary Angiogenesis 
Even though capillary density is the most commonly assessed histological 
measure of perfusion in pre-clinical models, a context for the interpretation of these 
findings is unclear (159).  As reviewed by Waters et al. (159), while capillary density is 
directly correlated with oxidative capacity and muscle endurance in the absence of 
disease, increased capillary density was correlated with the degree of skeletal muscle 
hypoxia (and not increased perfusion) in the presence of PAD.  In addition, the common 
phenomenon of muscle atrophy in hindlimb ischemia models complicates the 
measurement of capillary density (in capillaries per mm2) as this value is influenced by 
changes in muscle fiber size (159).  In his review, Wahlberg identifies a lack of reports in 
the literature that demonstrate active angiogenesis occurring in the chronically ischemic 
limb of patients (158).  Simons review suggests that increased capillary number can 
increase blood flow 2-3X but that collateral growth can increase blood flow 20-30X 
(131).  Scholz et al. demonstrated that the largest increase in capillary density occurred in 
the strain of mice that showed the poorest recovery of hindlimb perfusion (Balb/C) while 
capillary density was unchanged in the mice that experienced the greatest recovery of 
hindlimb perfusion (C57BL/6) (121).  Hershey et al. showed that increased capillary 
density occurred at the same time as reduced resting blood flow while the growth of 
collateral vessels coincided with a large functional improvement in the reserve blood 
flow capacity of the limb (62).  Thus, increases in capillary density and improved 
hindlimb perfusion were not linked (62).  Emanueli et al. showed in the ischemic rat 
hindlimb that hemodynamic improvement can occur in an absence of changes in 
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 capillarity (47).  Sanne and Sivertsson measured hindlimb resistance and observed that 
the resistance of the “local” vascular bed (distal to the collaterals, which would include 
the capillaries) did not change over the course of 5 weeks after femoral arterial occlusion 
while the collateral vessel resistance was reduced (112).  Unthank et al. (150) and Lash et 
al. (76) demonstrated that: 1) distal tissue perfusion is determined by the vascular 
resistance of the bypass collaterals and the distal microvasculature, 2) the collateral 
vessels account for the majority of vascular resistance distal to occlusion, and 3) the 
greatest decrease in vascular resistance occurs in the collaterals (not the distal 
microvasculature) as compensation to occlusion occurs and hindlimb perfusion is 
increased after femoral artery ligation in the rat.  Terjung’s group corroborated the 
findings of Unthank and Lash, demonstrating that collateral resistance but not distal 
tissue resistance is the major site of resistance determining downstream blood flow after 
femoral artery in the rat (75-85% total limb resistance) (163).  Lastly, not only does the 
microvasculature comprise a small amount of hindlimb resistance after arterial occlusion, 
but Bohlen et al. (7) and Fronek and Zweifach (49) have also previously shown that 
capillaries themselves normally comprise only a small component of skeletal muscle 
microvascular resistance in the absence of arterial occlusion.  Indeed standard 
physiologic textbooks state: 1) vascular resistance in the non-diseased limb is primarily 
controlled by the pre-capillary arterioles because of their ability to regulate vascular tone 
due to the presence of smooth muscle within their wall and 2) that the total resistance of 
the capillaries is much less than that of the arterioles due to the capillaries tremendous 
cross-sectional area (127).  Thus, these data suggest not only that angiogenesis may not 
be of primary importance in perfusion of the chronically ischemic limb in patients but 
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 also that collateral growth seems to be more important in restoring perfusion in animal 
models of hindlimb ischemia than angiogenesis. 
Additional evidence for collateral growth being more beneficial at restoring 
hindlimb perfusion comes from Poiseuille’s law.  Poiseuille’s law dictates that vascular 
resistance is inversely proportional to the fourth power of radius.  Thus, small changes in 
collateral diameter can be responsible for extremely large changes in collateral 
conductance (147).  Poiseuille’s Law estimates the volume flow (Q) of a fluid through a 
tube of length (L) and radius (r) as follows: 
Q = πr4ΔP/8Lη 
where ΔP is the change in pressure from the beginning to the end of the tube and η is the 
viscosity of the fluid, assuming Newtonian fluid dynamics.  Hemodynamic resistance is 
defined as the energy drop along the vessel divided by the volume flow and, as long as 
gravitational potential energy and kinetic energy are considered to be small, the ΔP can 
represent the energy loss along the vessel.  Therefore, Poiseuille’s equation can be re-
written to calculate vascular resistance: 
     R = 8Lη/πr4 
Poiseuille’s law has been invoked to suggest the importance of collateral growth 
over capillary angiogenesis in several ways.  Rockstroh and Brown (109) used the 
Poiseuille equation to calculate the theoretical flow capacity of various caliber tubes: a 1 
mm tube will have a flow capacity 7.7 times that of a 0.6 mm tube, and 39 times that of a 
0.4 mm tube.  They then used a cineangiographic approach to directly quantify the lumen 
caliber and flow capacity of dominant collaterals by measuring the transit time of the dye 
through the collateral as well as the collateral length and diameter (109).  This direct 
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 method demonstrated the flow in the 1 mm diameter collateral was 6.5 times that through 
the 0.6 mm collateral and 32 times that through the 0.4 mm collateral, in agreement with 
what was calculated from Poiseuille’s equation (109).  Based on both this direct and 
theoretical evidence, Rockstroh and Brown then concluded the 2-3 largest collaterals in 
the angiographically visible spectrum carried the majority of flow capacity of a collateral 
network (109).  Similarly, De Lussanet et al. utilized magnetic resonance angiography 
(MRA) and Poiseuille’s law to determine that almost 100% of total blood flow in the 
rabbit hindlimb after femoral artery occlusion is supplied by collaterals visible in both 
MRA and X-ray angiography (XRA; i.e., collaterals ≥0.3 mm), while collaterals visible 
only in XRA (i.e., collaterals 0.1-0.3 mm in diameter) contributed little to blood flow 
(36).  Scholz et al. (121) reported that even though a 1.7X increase in capillary density 
was observed in the Balb/C mice, this did not adequately restore perfusion and would 
only theoretically restore perfusion ~1.7X.  Conversely, the C57BL/6 mice they studied 
experienced extensive collateral enlargement, minimal increases in capillary density, and 
restored perfusion ~4X (121).  Upon femoral artery occlusion in our mice, we have 
observed 50-60 µm pre-existent collateral vessels enlarging ~2.5 fold to compensate for 
the occlusion of the ~350 µm femoral artery, providing ~80% of the hindlimb perfusion 
that was present before the occlusion.  If compensation to occlusion occurs through a 
mechanism in which the pre-existent vessels only increase in number but do not enlarge, 
as is the case with angiogenesis, Poiseuille’s equation states it would take 2401 of the 50-
60 µm pre-existent collateral pathways or 24 million of the ~5 µm (4) capillaries to 
completely compensate for the occluded femoral artery.  However, it would take only 
~61 of the enlarged collaterals (~125 µm in diameter) to compensate for femoral arterial 
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 occlusion.  This is one reason Schaper suggested an impossible number of capillaries 
would be needed to compensate for an occluded parent artery, because the tissue volume 
created by such an increase in capillarity would in essence replace the organ to be 
perfused with blood (115).  Indeed, Scholz et al. observed a permanent flow deficit in 
Balb/C and sv129 mice even though the combined diameter and tissue mass of the six 
collateral arteries identified bypassing the site of femoral occlusion exceeded that of the 
original femoral artery (121).  This was attributed to increased length of the collaterals 
versus the length of the occluded segment of the femoral artery (a >2X increase in 
length), increased collateral vessel tortuosity, and the energy losses predicted by 
Poiseuille’s law when one larger vessel is replaced by several smaller ones (121).     
In their review, Heil and Schaper (56) also suggest that the arrangement of having 
multiple collaterals replace a single occluded parent artery is not efficient according to 
Poiseuille’s law because the energy losses created by the additional resistances of the 
contributing vessels are additive.  These authors go on to suggest that this is the reason 
only a few collaterals which experience the greatest degree of enlargement eventually 
remain while the rest of the many collaterals that initially enlarged undergo regression 
(56).  Thus, having a network of multiple vessels compensate for the occlusion of one 
main artery, as would occur with angiogenesis, is energetically unfavorable.  Heil and 
Schaper (56) also point out that in several different animal studies collateral vessels were 
able to recover only ~40% of the pre-occlusion maximal conductance and raise the 
question whether collateral growth will ever be able to completely compensate for an 
occluded parent artery.  Subsequently, though, their group was able to demonstrate that 
collaterals can completely compensate for an occluded parent artery, if fluid shear stress 
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 in the expanding collaterals is not allowed to normalize (45).  In addition, Rissanen et al. 
(105) site Poiseuille’s law to suggest that collateral blood flow is more critically 
dependant on vessel diameter than on vessel number and also observed that the response 
to femoral occlusion consisted mainly of the enlargement of pre-existing collateral 
vessels as opposed to increased capillary density.  Similarly, White et al. (160) excluded 
vessels ≤20 µm from their analysis because Poiseuille’s law indicates that the flow 
through vessels of this size or smaller is miniscule versus the flow through larger vessels.   
Therefore, because: 1) experimental evidence suggests hindlimb resistance is 
more dependant on collateral enlargement than on capillary proliferation after femoral 
occlusion, 2) enlargement of collaterals can provide significantly more flow than 
proliferation of capillaries, 3) volume flow is directly proportional to the fourth power of 
the radius, and 4) the energy losses to the system are greater when adding new vessels 
(i.e., capillary proliferation) rather then expanding the vessels already present (i.e., 
collateral growth), it appears that collateral growth is more potent mechanism for 
maintaining hindlimb perfusion than angiogenesis. 
The Shift in Focus from Collateral Growth to Therapeutic Angiogenesis 
Judah Folkman “fathered” the field of angiogenesis when he proposed in the New 
England Journal of Medicine in 1971 that: 1) tumors depend on the active induction and 
continuous growth of new blood vessels (angiogenesis) to survive and expand (48, 54), 2) 
that tumors release diffusible factors that stimulate endothelial cell proliferation and 
capillary formation, and 3) that anti-angiogenesis therapy could possibly control tumor 
growth; as reviewed by Zetter (165).  Thus, Folkman was the first to propose anti-
angiogenic therapy.  Based on Folkman’s assertion that tumors secrete factors which 
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 stimulate angiogenesis, many researchers set out to investigate the hypothesis that the 
stimulation of new capillary growth could be beneficial for the treatment or prevention of 
pathological clinical situations characterized by a local decreased number of blood 
vessels or decreased blood flow (66).  Indeed, as early as 1977 there was an article in 
Lancet entitled “Tumour angiogenesis factor for revascularisation in ischaemia and 
myocardial infarction.” by Svet-Moldavsky and Chimishkyan (136).  This soon 
blossomed into an entire field of its own termed “therapeutic angiogenesis” (66).  Partly 
due to the fact that the molecular mechanisms underlying the process of angiogenesis 
were becoming more clearly understood than those that mediate collateral growth, a shift 
in the focus of research from collateral growth to therapeutic angiogenesis began to 
occur.  Jeffrey Isner (69), who would become one of the leaders in the field of therapeutic 
angiogenesis, said that angiogenesis “presumably accounts for some, if not most, 
collateral vessels which constitute ‘auto-bypass’ conduits in patients with vascular 
disease”.  Thus, according to this statement, the mechanism for collateral development is 
suggested to be capillary sprouting and not the enlargement of pre-existing bypass vessels 
as was identified by the early studies and was described in medical texts.  Statements like 
this from well respected leaders in the field like Isner implying angiogenesis is the source 
of collateral vessels combined with the prevalence of angiogenic molecular therapy based 
studies further exacerbated the shift in focus from the study of pre-existing collaterals to 
therapies focused on angiogenesis.  Indeed, this shift in focus led Schaper to suggest that, 
by 1984-85, the pioneering work of the animal physiologists on collateral growth (as 
outlined above) had all but been forgotten (113).  However, novel therapies to enhance 
the growth of pre-existent collaterals are still needed because the efficacy of angiogenic 
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 growth factor therapy for treatment of CLI is still not well established (74) and growth 
factor therapy is best investigated in the context of a placebo-controlled trial (64).  The 
failures of these molecular angiogenic therapies have led investigators to question the 
effectiveness of therapeutic angiogenesis as a whole (74).  Indeed, the evidence presented 
in the previous section further suggests that therapeutically enhancing collateral growth 
may be able to restore hindlimb perfusion more adequately than enhancing angiogenesis. 
The Strict Definition of Arteriogenesis has caused some Confusion in the Field of 
Collateral Growth Research 
Schaper and colleagues have been one of the leading groups trying to shift the 
focus back on to collaterals from capillary angiogenesis arguing that “Arteriogenesis is 
by far the most efficient adaptive mechanism for the survival of ischemic limbs or 
internal organs such as heart and brain because of its ability to conduct, after adaptive 
growth, relatively large blood volumes per unit of time… an increase in the number of 
capillaries, the result of stimulated angiogenesis, is unable to do that.” (13).  Thus, 
therapeutically enhancing collateral growth as opposed to the growth and/or proliferation 
of the distal capillaries has tremendous potential for improving the morbidity and 
mortality caused by arterial occlusion within PAD by enhancing tissue perfusion more 
effectively than angiogenesis.  However, Schaper’s “arteriogenesis” model of collateral 
growth puts forth a strict definition of what vessels can become collaterals and what 
characteristics these collateral vessels display: suggesting that only arterioles 10-30 µm in 
diameter can become collaterals, that these vessels are capable of enlarging 10-25 fold, 
and that collaterals will display the characteristics of increased intimal cell number, neo-
intimal formation, and vascular wall thinning (14).  This strict definition of 
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 arteriogenesis/collateral growth has only added to the confusion in the field because 
much of what other investigators would consider to be collateral growth falls within a 
much more general definition: small inter-connecting arteries 100-300 µm in diameter 
enlarging 2-3 fold and displaying increased intimal cell number, no neo-intimal 
formation, and thickening of the vascular wall (24, 25, 31, 53, 63, 81, 100, 118, 120, 121, 
148, 168).   
What should now be done to advance the field of therapeutic collateral growth? 
If the goal is to derive therapies translatable into the clinic, then scientifically 
rigorous translational studies carried out in appropriate (diseased) animal models will be 
necessary to develop and assess potential therapies before their use in humans (153, 159).  
Thus, to advance the field of collateral growth, future studies must: investigate collateral 
growth in animal models with appropriate co-morbidities (such as age, atherosclerosis, 
diabetes, etc.), occlude vessels in anatomical locations relevant to human disease (if 
feasible, and gradual occlusion would be preferred to acute ligation), focus on the process 
that will best enhance limb perfusion (collateral growth not angiogenesis), use 
appropriate methods to assess collateral growth, and functionally identify and study only 
the most important enlarging collateral vessels (excluding the possibly confounding 
process of collateral regression).  In addition, a recent review by van Weel et al. (157) has 
suggested combining therapies to induce both angiogenesis and arteriogenesis in order to 
both increase gas exchange in ischemic tissues as well as enhance the delivery of blood 
flow to the compromised limb.  Indeed, data presented later in this thesis (Chapter II) will 
suggest that both collateral growth as well as the preservation of the distal vasculature are 
necessary for adequate perfusion of the hindlimb measured via laser Doppler perfusion 
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 imaging.  Van Weel et al. (157) goes on to state that they had success (measured via ABI 
and improved ulcer healing) using VEGF gene transfer into diabetic patients with critical 
limb ischemia in a double-blinded, placebo controlled clinical trial; suggesting that the 
ischemic limbs of diseased patients are amenable to therapeutic intervention. 
In conclusion, the current pre-clinical rodent models only roughly approximate 
the clinical human situation.  A review of PAD identified several primary properties 
which should be incorporated into future animal models, including: 1) gradual 
onset/occlusion is more relevant (but may be more difficult to mimic, based on the 
animal models used), 2) infrainguinal occlusion most frequently occurs in the short 
segment of the femoral artery, 3) pre-existing collaterals arising from the profunda 
femoral artery are involved for compensating for occlusions at this site (as long as they 
remain intact), and 4) the patient populations most at risk for significant morbidity and 
mortality associated with PAD are those who are older, have diabetes, and who smoke.  
The three endogenous mechanisms of collateral growth, angiogenesis, and 
vasculogenesis were identified as potentially able to restore hindlimb perfusion upon 
arterial occlusion; however, experimental as well as theoretical evidence suggests 
collateral growth is the most important and/or most able to restore perfusion to pre-
occlusion levels.  In addition, 1) major limitations to the animal models and analytical 
methods currently utilized to study angio-/arterio-genesis and collateral growth were 
identified, 2) a shift of focus and resources by some but not all investigators away from 
collateral growth on to therapeutic angiogenesis was discussed, and 3) the strict definition 
of arteriogenesis has caused additional confusion regarding which vessels are the most 
important to focus on in regards to collateral growth.  Therefore, the focus of my thesis 
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 work will be to: 1) address the current state of confusion in the field of collateral growth 
using animal models and assessment methodologies appropriate for the study of collateral 
growth (Chapters I-III), 2) identify the most important collateral vessels in providing 
distal perfusion in the hindlimb (Chapter I), 3) determine what characteristic changes can 
be observed in the vascular wall of growing collaterals between multiple species (Chapter 
I), and 4) to investigate mechanisms mediating the growth of the most important 
collaterals in both young, healthy and aged animals (Chapter II and III) in response to 
femoral arterial occlusion. 
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 CHAPTER I 
Characteristics of Major Collateral Arteries in the Peripheral Circulation 
of Humans, Pigs, Rats, and Mice 
Abstract: 
Improvement in tissue perfusion after focal arterial occlusion in the peripheral 
circulation results mostly from increased conductance in collateral vessels rather than the 
distal microvasculature.  Although post-occlusion tissue perfusion is determined 
primarily by the largest collaterals, controversy exists regarding the size of vessels which 
enlarge to become major collaterals, the nature of their wall remodeling, and degree of 
tortuosity.  In addition, recent studies have suggested that important aspects of collateral 
growth may differ between the small animals most commonly used as experimental 
models and large species, including humans.  To clarify these issues, collateral arteries 
resulting from focal arterial occlusion were analyzed and compared in four species; 
humans, miniature swine, rats, and mice.  The presence of pre-existing collaterals in the 
porcine hindlimb was demonstrated by a rapid recovery of blood flow after acute 
superficial femoral artery occlusion.  Angiograms (humans and pigs) and vascular casting 
(rats and mice) demonstrated that the major collaterals in all species formed from pre-
existing small arteries.  Tortuosity of collaterals varied considerably with major segments 
displaying limited convolution.  The pre-existing arteries which formed major collaterals 
enlarged <3-fold while other pre-existing collateral pathways regressed.  Collateral 
diameter ranged from <0.1 mm in mice to >1 mm in pigs.  Histological examination of 
collateral cross-sections in pigs, rats, and mice revealed dramatic increases in intimal cell 
number.  Neointimal formation was observed in regressing but not enlarging collaterals.  
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 While the results indicate that the major collaterals in small and large species share many 
characteristics including development from small arteries, not arterioles, intimal cell 
recruitment/proliferation, and varying degrees of tortuosity; the substantial variation in 
size and wall thickness between species could significantly impact the diffusion of 
paracrine factors and thereby the remodeling process.  Conflicting data in previous 
studies might be explained by differences between enlarging and regressing collaterals.   
 
Key Words: arteriogenesis, Ossabaw, collateral vessel regression,  
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 Introduction:  
Vascular adaptations to arterial occlusion in the peripheral circulation involve all 
vessels from capillaries to collateral arteries.  While there is no consensus as to which 
vascular adaptations are most important (17), a number of studies provide evidence that 
changes in collateral vessel conductance or resistance is most important, both 
immediately and long-term after abrupt arterial occlusion (76, 111, 112, 149, 150, 163).  
Certainly collateral vessels are considered to be largely responsible for the restoration of 
blood flow to distal tissues after abrupt arterial ligation in the human leg (37, 51).  
Available evidence suggests that the largest collaterals are the most important in tissue 
perfusion (36, 81, 121).   
Controversy exists regarding the vessels from which collaterals develop, 
including the large (major) collaterals.  It has been proposed that the tortuous portion of 
collaterals may represent de novo vascular formation (137).  In support of new vessel 
formation, high resolution micro-CT has demonstrated an increased number of small-to-
medium sized vessels after mouse iliac-femoral artery and vein ligation (79).  Other 
investigators have questioned if newly formed vessels can have functional significance 
(55, 57) and many studies have concluded that collaterals are formed by pre-existing 
vessels.  Potential pre-existing vessels forming collateral pathways include arcading 
arterioles and arteries.  Early studies of vascular adaptation to arterial occlusion in the 
peripheral circulation focused on small arteries, but many current studies focus on 
capillaries or small arterioles.  While early studies reported collateral growth to involve a 
2-3-fold expansion of small arteries (31, 81), some recent studies and reviews report that 
arteriogenesis, a term commonly used as a synonym for collateral growth, involves small 
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 arterioles ≤50 μm which enlarge 10-25-fold to become conduit collateral arteries (14, 
117, 155).  
The stimulus for both collateral growth and arteriogenesis in the peripheral 
circulation is thought to be increased shear stress.  But the phenotype of outward 
remodeling in response to elevated shear is reported to be quite different for large through 
small arteries, versus the small arterioles undergoing arteriogenesis.  Studies of arteries 
have reported endothelial proliferation and maintenance of, or increased, medial 
thickness (15, 83, 126, 130, 142-145, 148), while small arterioles are indicated to 
undergo medial thinning and intimal destruction with neointimal formation (63, 114, 
119). 
The objective of this study was to characterize the major collaterals which 
develop subsequent to focal arterial occlusion in the peripheral circulation of multiple 
species.  To accomplish this objective, 1) human angiograms with focal infrainguinal 
arterial occlusion were studied to identify the type of vessels which enlarged to become 
major collaterals in humans; 2) common femoral artery flow in miniature pigs was 
measured before and after acute compression of the superficial femoral artery to assess 
the presence of pre-existing collaterals; 3) the arterial pathways from which major 
collaterals developed in the hindlimb of miniature pigs, rats, and mice after femoral 
artery ligation were identified from angiograms and vascular casts; and 4) arterial cross-
sections of the major collaterals and similar vessels in contralateral limbs were compared.  
Collateral vessel tortuosity was also evaluated because some investigators utilize this trait 
as the primary method to identify collaterals. 
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 Materials/methods: 
Human Studies 
Past angiograms of patients with lower extremity arterial occlusive disease were 
obtained by the physician authors with approval from the IUPUI/Clarian Institutional 
Review Board.  After removal of all identifying information, these angiograms were used 
to evaluate the vessels which formed collaterals after focal occlusion.  The human 
angiograms were obtained by means of routine angiographic protocols through a femoral 
access via a Seldinger approach followed by a standard lower extremity angiogram.   
Animals 
Male Ossabaw miniature swine that were gonadally intact were studied as fully 
mature adults at ~20 months of age.  Male WKY rats and C57BL/6 mice purchased from 
Harlan (Indianapolis, IN) were studied at 3-6 months of age.  Animals were housed in the 
Laboratory Animal Resource Center at Indiana University School of Medicine which is 
fully accredited through the Association for Assessment and Accreditation of Laboratory 
Animal Care International.  The mice were part of another study (39), but no duplicate 
data are presented.  All animal procedures were approved by the Institutional Animal 
Care and Use Committee of the Indiana University School of Medicine and complied 
fully with recommendations outlined by the National Research Council in the Guide for 
the Care and Use of Laboratory Animals (104).   
Pig Procedures 
Femoral artery ligation was performed in the miniature swine during a routine 
procedure for cardiac stenting as previously described (44).  In brief, the right superficial 
femoral artery (SFA) underwent double ligation (1 cm apart) using sterile silk sutures 
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 (Figure 1).  Four weeks later the pigs were prepared for lower extremity hemodynamic 
assessment and angiograms.  The pigs were sedated with a mixture of telazol (5.0-6.0 
mg/kg) and xylazine (2.2 mg/kg) via an intramuscular neck injection followed by 
atropine (0.05 mg/kg).  Once adequate sedation was achieved, the pigs were transported 
to the operating room where they were pre-oxygenated and given general gaseous 
anesthesia using isofluorane.  The anterior neck and bilateral medial groin areas were 
shaved using electric clippers in preparation for vascular access.  After proper positioning 
of the pig on the operating table, a right carotid arterial cutdown was performed using 
Bovie cautery and blunt dissection.  An arteriotomy was made in the right carotid artery 
and an introducer catheter was placed using the Seldinger technique.  A guidewire was 
placed into the introducer catheter and used to insert a guiding catheter into the hindlimb 
arterial system.  Intravascular ultrasound was used to determine common femoral arterial 
diameter.  After accessing the artery with a guiding catheter, a 0.014-inch diameter 
guidewire or a ComboWire™XT (Volcano Corporation, Rancho Cordova, CA) was 
advanced down the artery and the intravascular ultrasound catheter (35 MHz, Ultracross, 
Boston Scientific/SciMed, Maple Grove, MN) was advanced over the flow wire and 
positioned (91, 135). 
Hemodynamic measurements were performed using the guiding catheter that 
provided proximal (typically aortic) blood pressure and the ComboWire™XT which 
provided continuous distal pressure and blood flow velocity readings.  These 
measurements were recorded with the tip of the ComboWire advanced out of the guiding 
catheter in the common femoral artery.  The Doppler signals were continuously recorded 
both as instantaneous peak velocity (IPV) and averaged peak velocity (APV) values.  
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 Each APV value was calculated on-line by the ComboWire system as an average of 
instantaneous peak velocity over 2 consecutive cardiac cycles.   
 The tip of the guiding catheter was placed in the external iliac and common 
femoral artery to perform angiography of both proximal hindlimbs using C-arm 
fluoroscopy as described in detail (135).  Angiograms were performed in real-time with 
Hypaque 60 or 75 contrast using a power injector set at 5 seconds (30 ml).  At the 
conclusion of the experiment, the animal was euthanized by excision of the heart.  
Collaterals were identified from the frame by frame analysis of the angiogram as vessels 
through which the contrast agent was observed to enter the distal femoral artery (Figure 
3).  Collateral diameter was measured using the ECG electrode as a spatial calibration 
marker and was also expressed relative to the profunda (deep) femoral artery.   
Rat and Mouse Procedures 
Animals were anesthetized via 2% isofluorane.  The ventral surface of their right 
hindlimb was shaved and sterilized by cleansing with iodine and an alcohol prep pad.  
Animals were placed on a heating pad to maintain body temperature throughout the 
procedure.  Sterile surgical techniques were observed at all times. 
In rats, the superficial femoral artery was carefully dissected away from the vein 
and nerve and ligated with sterilized silk at the level of the inguinal ligament (Figure 1).  
In mice, a femoral artery single ligation model to produce moderate ischemia (128) was 
performed in which the femoral artery was carefully dissected away from the vein and 
ligated with sterilized silk at a point just distal to the superficial epigastric artery (Figure 
1).  The incisions were closed with sterile resorbable suture and the rats and mice were 
given buprinorphen (0.05 mg/kg) subcutaneously for pain maintenance.   
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 Perfusion fixation was performed two weeks post-ligation via an aortic cannula at 
physiologic pressure (~100 mmHg) with 4% Zn-formalin after clearing the blood and 
dilating the vasculature (0.9% sterile saline, 10 mM adenosine, 1 mM sodium 
nitroprusside, and 2.5 U/ml heparin).  The vascular casting agent (Microfil®, Flow Tech 
Inc., Carver, MA) was then slowly injected by hand and stopped as soon as it entered the 
saphenous artery as visualized via intravital microscopy.  After curing of the casting 
agent overnight at 4°C, the collateral pathway, beginning with the re-entry segment, was 
then dissected through the midzone region.  The same pathway was identified in the 
contralateral limb, dissected, and utilized as the same-animal control.  Arterial sections 
from the mid-zone region were excised. 
Histology and Morphometry 
The excised collateral vessels and their contralateral controls were placed in 4% 
Zn-formalin for 24 hours before histological processing.  Vessel tissues were embedded 
in plastic, sectioned, and stained with Lee’s Methylene Blue (rats and mice) or embedded 
in paraffin and stained with Hematoxylin and Eosin (pigs).  Images were obtained with a 
Leica DM 5000B microscope with 5-40X objectives using a Diagnostic Instruments Inc. 
Spot RTKE camera.  Lumen circumference was traced using Image J and the cross-
sectional diameter was calculated.   
Statistical Analysis 
Statistical analyses were performed via ANOVA (SigmaStat 3.0, Systat Software, 
Inc., San Jose, CA).  When the ANOVA identified significant differences (P≤0.05), the 
Holm-Sidak method was used for pairwise multiple comparisons.  Data are expressed as 
means ± SEM.  Humans, n = 3; Pigs, n = 12; Rats, n = 12; and Mice, n = 7.
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 Results: 
Hemodynamic Evidence of Pre-existing Collaterals 
In the miniature swine, APV at baseline in the patent left common femoral was 
24±1.6 cm/sec.  With acute occlusion of the superficial femoral artery, the APV initially 
decreased to ~50% of baseline and then recovered to 88±3.9% of baseline within 3 
minutes.  This recovery in APV after the initial decrease is consistent with earlier studies 
in humans (84, 124, 125), dogs (42, 111) and rats (149) and is best explained by the 
dilation of pre-existing vessels which form alternative or collateral pathways.  
Major Collateral Pathways and Tortuosity 
Human angiograms with focal arterial occlusion in the lower extremity are shown 
in Figure 2.  With superficial femoral artery (SFA) occlusion above the knee in Figure 
2A, multiple collateral arteries are seen arising from proximal SFA branches and re-
inserting into the distal SFA.  Figure 2B shows similar bridging collaterals for popliteal 
artery occlusion with large collaterals originating from the proximal popliteal, bypassing 
the occlusion, and re-inserting into the distal popliteal artery.  The angiogram in Figure 
2C and D shows two focal occlusions in the superficial femoral artery with proximal 
collaterals arising from the profunda femoral.  Major collaterals in all angiograms include 
the geniculate arteries.  Note that some collaterals are more tortuous than others and most 
have segments which are relatively straight. 
In pigs, major collaterals were identified as vessels which reconstituted the 
femoral system distal to the occlusion site.  This was accomplished by viewing sequential 
frames of the angiogram as illustrated in Figure 3.  All collaterals were observed to 
originate from the gluteal artery, profunda (deep) femoral artery, or proximal SFA shown 
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 in Figure 3B.  The contrast agent enters the distal SFA through three collateral pathways 
identified by arrows in Figure 3C and continues downstream (Figures 3D and E).  There 
was an animal average of 1.3±0.17, 1.5±0.19 and 2.7±0.33 collaterals, respectively, 
which branched from the proximal SFA, gluteal, and profunda femoral arteries.  The 
collateral branches originating from the gluteal artery consistently formed the largest 
collaterals in our porcine hindlimb model.  As percent of the profunda femoral artery, the 
collateral branches from the gluteal artery averaged 37±3.0% vs. 26±2.1% and 29±1.2% 
for collaterals branching from the SFA and profunda femoral artery.  Only a subset of 
these major collaterals demonstrated tortuosity.  In other miniature and farm pigs with 
similar arterial ligation, collaterals have been reported to branch from the proximal SFA 
and profunda femoral, but not the gluteal artery (14), perhaps due to subspecies 
differences.  The average diameter of the collateral mid-zone region based upon 
calibration with the ECG electrode was 1.1±0.05 mm, versus an average diameter of 3.6 
mm for the profunda and 4.9 mm for the common femoral artery.  Pre-existing stems and 
re-entry points but not interconnecting mid-zone regions could typically be visualized in 
the same-animal control limbs (Figure 3G).  Such interconnections must be pre-existing 
(but below the angiogram resolution) or the APV would have been severely compromised 
after acute arterial compression.  
In WKY rats, major collaterals were identified by vascular casting.  We had 
anticipated that the major collateral pathway would involve the perforating artery as 
previously reported (63, 100).  When initial experiments indicated this vessel was not 
consistently enlarged, we identified the superficial circumflex iliac artery and its 
proximal branch as the major collateral pathway most frequently demonstrating 
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 enlargement (Figure 4).  This anatomical pathway has previously been reported as a 
potential pre-existing collateral in the rat hindlimb (82).  As shown in Figure 4, the 
superficial circumflex iliac artery and its proximal branch is observed to be present but 
smaller in the contralateral control limb.  Similar to the major collaterals in the human 
and pig, the rat collaterals develop from pre-existing small arteries and have limited 
tortuosity.   
In mice, we observed the gracilis artery to be the major collateral pathway after 
femoral artery occlusion.  As shown in Figure 5, this vessel is both enlarged and more 
tortuous in the experimental than contralateral limb.  This is consistent with several 
previous reports (25, 121, 167). 
Collateral Vessel Wall Characteristics Including Collateral Size and Enlargement 
Micrographs of pig, rat, and mouse control and collateral cross-sections are 
presented in Figure 6.  A representative micrograph of a collateral branching from the 
porcine gluteal artery is shown in Figure 6A next to a similar sized artery from the 
contralateral limb.  Representative micrographs are shown for the rat superficial 
circumflex iliac artery from control and experimental limbs in Figure 6B.  Figure 6C 
shows typical micrographs of the rat perforating arteries in which the diameter of the 
perforating artery in the experimental limb was reduced relative to the same animal 
control limb.  Gracilis arteries from the control and experimental limbs of a mouse are 
presented in Figure 6D.  
Perhaps the most remarkable difference in the enlarged collaterals of all species is 
the increase in intimal cell number relative to the control limb.  A neointima was not 
observed in any of the pig collaterals nor in any of the superficial circumflex iliac or 
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 gracilis arteries of experimental limbs in rats and mice, respectively.  In general, the 
media was thicker in the enlarged collaterals of the experimental limbs than the controls 
in the contralateral limbs.  In mice the medial thickness of the control limb gracilis artery 
averaged 3.2±0.13 μm vs. 5.4±0.36 μm in the experimental limb.  The considerable 
difference in the diameter and thickness of collaterals from pigs compared to rats and 
especially mice is striking, as illustrated in Figure 6E. 
In rats and mice, diameters were determined from arterial cross-sections of the 
major collateral in the experimental limb and the identical pathway in the contralateral 
limb.  In rats, diameters were measured for both the perforating artery and superficial 
circumflex iliac arteries as both have been reported to be collaterals.  Relative to same 
animal control diameters, the perforating artery was enlarged in only 3 of 12 animals 
where paired observations were possible versus 8 of 12 rats for the superficial circumflex 
iliac.  As shown in Figure 7A, vessel diameters in these animals averaged 199±54.3 μm 
and 135±13.4 μm for the perforating and superficial circumflex iliac arteries in the 
control limbs and were 57±23.6 (P = 0.083) and 88±26.2% (P = 0.004) larger, 
respectively, in the experimental limbs.  Although the perforating artery formed a 
collateral pathway in rats, it was smaller in the experimental vs. control limbs in 9 of 12 
rats, averaging 50±8.2% of the same animal control limb (Figure 7A).   
Similar diameter measurements were made in mice and are reported in Figure 7B.  
The diameter of the gracilis artery in arterial cross-sections of control limbs averaged 
55±3.4 μm.  In the experimental limb, the diameter was 50±13.5% larger than in same 
animal control limbs.  
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 Discussion: 
This study was focused on the main collateral arteries in the human lower 
extremity and hindlimb of pigs, rats and mice.  Because of the exponential relationship 
between vessel radius and vascular resistance, the largest collaterals have been 
considered to be the most important in terms of tissue perfusion distal to the site of 
occlusion.  In the rabbit hindlimb, the largest collaterals have been reported to contribute 
nearly 100% of total resting flow (36).  In mice, major differences in hindlimb perfusion 
observed between various strains (121) after femoral artery ligation are explained by 
small differences in the expansion of the pre-existing vessels which form the major 
collaterals.  Our results from four species indicate that major collaterals develop from 
pre-existing, named, small arteries or their direct branches rather than arterioles, enlarge 
<3-fold rather than 10-25-fold, and are characterized by an increase in intimal cell 
number but not neo-intima formation.  The results also indicate that tortuosity is not 
necessarily a characteristic of the major collaterals.  An additional, often over-looked 
consideration is that some pre-existing small arteries which form collateral pathways 
undergo regression rather than enlargement. 
Importance of Pre-existing Pathways 
To our knowledge, the observations in the miniature swine of an initial drop in 
common femoral APV after acute SFA occlusion, followed by significant recovery 
represent the first demonstration in the pig hindlimb of functional pre-existing collaterals.  
These results are consistent with previous studies in the human leg reviewed below as 
well as studies in the dog (42, 111) and rat (149) hindlimb.  This increase in perfusion 
occurs concomitant with an elevation in arterial pressure distal to the site of acute 
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 occlusion (42, 111, 149), indicating that the primary compensation involves dilation of 
the pre-existing bypass collaterals rather than the distal microcirculation. 
The existence and role of pre-existing “mid-zone” collateral pathways has been 
debated since before Longland’s work in which he both reviewed and provided additional 
anatomical evidence for these vessels (81).  The clinical importance of pre-existing 
collateral vessels has been recognized since the 18th century, when surgeons like Anel, 
Desault, and Hunter utilized the concept of a collateral circulation as the basis for limb 
survival after large arterial ligations for the treatment of brachial and popliteal artery 
aneurysms (86, 116).  In 1910, Matas (84) described methods of determining the 
adequacy of the collateral circulation during temporary large artery occlusion, and he 
applied these methods to evaluate treatment options for limb aneurysms.  Further 
evidence of the importance of pre-existing collaterals came in 1945, when Debakey and 
Simeone (37) published a large volume of data that examined limb salvage rates in 
soldiers who had suffered major arterial injury.  These surgeons considered damage to the 
collateral circulation either by the injury or debridement to be a major factor influencing 
limb survival after arterial ligation.  Even after emergency iliac artery ligation in humans, 
the collateral circulation can be adequate to maintain limb perfusion and integrity (51).  
In the early 1950’s, human experiments by Shepherd (124, 125) demonstrated that an 
abrupt decrease in blood flow to the calf immediately after femoral artery compression 
was followed by a significant recovery to near normal levels within minutes.   
Primary Collateral Artery Pathways 
The above studies demonstrate the presence of pre-existing collateral pathways, 
but do not identify the vessels or establish that they are the ones which undergo luminal 
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 expansion.  For focal arterial occlusion near the knee, the small genicular arteries 
typically form the major collaterals as shown in our angiograms (Figure 2) and reported 
in human anatomical and surgical texts (78, 88) and reviews (122).  For more proximal or 
extensive occlusion, pre-existing collateral pathways involve branches from the internal 
iliac and profunda femoris arteries as well as branches from the external iliac and 
common femoral arteries (51, 88).  Our experiments in pigs, rats and mice demonstrate 
similar findings in that the major collaterals develop from small, named arteries or their 
direct branches.  This is similar to many previous reports as summarized in Table 1. 
It is important to note that variation occurs in the specific collateral pathways 
which become major collaterals and that regression of smaller collaterals occurs.  For 
example, in rats we observed the superficial circumflex iliac artery and its proximal 
branch to be the major collateral after proximal femoral ligation.  Previously published 
studies had identified the major collateral pathways to include the perforating artery 
connection to the popliteal artery (63) and a more proximal pathway that appears to 
connect to the muscular branch of the femoral artery proximal to the popliteal artery 
(100).  The specific pathways which become the major collaterals are likely determined 
by the ligation site and the size and length of the pre-existing anastomoses.  Our ligation 
of the femoral artery was performed proximal to the superficial circumflex iliac artery.  
In this case, branches between the internal iliac and superficial circumflex iliac provide a 
significantly shorter collateral path than the perforating artery which connects the internal 
iliac to the popliteal artery.  At 2 weeks post-ligation we observed a decrease in the cross-
sectional diameter of the perforating artery in most rats (9 of 12; Figure 7A).  Herzog et 
al. (63) have previously reported the diameter of this artery to be increased 7 days after 
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 femoral artery ligation and then to decrease in size.  Such a regression in collateral 
diameter is consistent with reports that only a few of the collaterals that initially enlarge 
will remain as a major compensator (81, 117).  This regression is thought to result from 
decreases in shear stress as other collaterals enlarge (45, 117).  Such a regression of 
collaterals was first reported by Longland (81) and more recently by others (63, 97, 115). 
Collateral Diameters and Percent Enlargement 
Comparison of identical collateral midzones in experimental and contralateral 
control limbs required vascular casting and was performed only in rats and mice.  
Because our measurements of initial and final collateral artery size differ substantially 
from some recent studies (14, 119) and reviews typically indicate arterioles and not small 
arteries to be the “substrates” of arteriogenesis (117, 158), we identified additional 
studies which used angiograms or vascular casting and reported diameters of major 
collaterals that develop from pre-existing vessels.  These results are presented in Table 1.  
The majority of the studies indicated the pre-existing collateral vessel to be an 
anatomically named small artery; the gracilis artery in mice and the perforating artery in 
rats.  The range of initial collateral artery size was 10-75 µm for mice, 140-230 µm for 
rats, 50-300 µm for rabbits, 150 µm for dogs, and 10-30 µm for pigs.  Only 2 of the 14 
studies reviewed reported collateral diameter enlargement ≥3-fold.  One of these studies 
reported the initial size to be 10-30 µm; values significantly lower than the other reports.  
Neither of these two studies indicated how the vessels examined histologically were 
identified as pre-existing collateral mid-zones.  
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 Collateral Wall Characteristics 
Both wall thinning (16) and thickening (77, 148) have been reported for 
collaterals in different vascular beds and at different stages of development (16).  Studies 
examining pathways that develop from small arteries consistently show medial 
thickening occurs early (Table 1), as observed in this study.  Fragmentation of the 
internal elastic lamina and neointimal formation have also been reported as early events 
in collateral remodeling in heart and hindlimb (60, 63, 114, 119).  But these studies did 
not distinguish between major and regressing collaterals.  Fragmentation and neo-intimal 
formation were not observed in the major collaterals of any species in the current study 
and are not apparent in micrographs presented in many other studies of major collaterals 
(Table 1).  The increase in intimal cell number without neointima formation was a 
consistent observation in hindlimb collaterals of pigs, rats and mice (Figure 6) and similar 
to our previous reports in mesenteric collaterals (126, 148).  This phenotype is also 
consistent with earlier studies of shear-mediated vascular remodeling in large and small 
arteries (126, 130, 144, 145, 148).  The increase in intimal cell number in our vessels is 
most likely due to flow-induced endothelial cell proliferation (126, 129, 144), but cell 
recruitment may also be involved (129).  The intimal cell nuclei have a size and 
orientation consistent with endothelial cells and immunostaining indicates the intimal 
cells are eNOS, CD31 positive and CD45, ED2 negative (39, 126, 144); polyploid or 
multinucleated cells were not observed in the intima.   
Species Comparisons 
Our results, together with earlier work referenced above, demonstrate that basic 
similarities exist between the major collateral vessels in small to large species, including 
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 development from pre-existing small arteries, degree of luminal enlargement, and intimal 
cell proliferation/recruitment.  However, preclinical studies of novel therapies in small 
species have had much greater efficacy than comparable therapies in clinical trials (see 
reviews (153, 159)).  As a consequence, some investigators have called for improved 
models of peripheral arterial occlusive disease (159) and others have questioned if 
collateral growth in small species, especially mice, accurately represents what occurs in 
larger species, specifically man (14, 153). 
There are multiple reasons why collateral growth might be different between 
small and large species.  Luminal and wall dimensions in the major collaterals of mice 
and pigs (Figure 6) differ by ~10-fold.  Based upon the differences in the amount of new 
tissue needed to produce fully remodeled collaterals in mice versus larger species, it has 
been proposed that the time course of remodeling may differ substantially (14).  All wall 
layers are involved in the remodeling of collateral vessels.  The media and adventitia of 
larger species are far thicker than in mice and consequently the ratio of adventitial and 
smooth muscles cells to endothelial cells is much greater in larger than smaller species.  
This could greatly impact the relative amount of growth modulators produced by various 
layers.  The diffusion distance for paracrine factors is much greater in larger species.  
Reactive nitrogen and oxygen species are considered to have important roles in the 
promotion and impairment of collateral growth (87, 89, 101, 103, 108) and diffusion 
distances could have an important impact on reactive species concentrations in various 
wall layers.  The vasa vasorum can have an important role in arterial remodeling (2).  
Although it is much more developed in small arteries of larger species, it is unknown if or 
how the vasa vasorum influences the growth of major collaterals.    
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 While small animals offer advantages which have been previously reviewed (14, 
159), there are compelling reasons why preclinical evaluation of novel therapies to 
promote collateral growth should include large animals models.  In addition to the above 
arguments, therapeutic delivery and methods of assessment can be identical in large 
animals such as the miniature pig and humans.  Pigs also have a cardiovascular system 
that much more closely resembles the human than smaller species.  This includes 
hemodynamics (flow and pulse rate), vascular dimensions and branching patterns.  As an 
example of the latter, rats do not have a profunda (deep) femoral artery (52).  Lipid 
metabolism and serum lipoprotein distribution in pigs are also similar to humans (40).  
Additional advantages of large animal models such as the pig include the ability to obtain 
large blood samples.  Hemodynamic measurements can be made which are difficult if not 
impossible in rodents.  Chronic instrumentation and longitudinal studies are far more 
feasible.  The same instruments and techniques (e.g. Duplex ultrasound, MRI, 
angiograms) can be used to evaluate disease in both man and pig.   
Study Limitations 
This investigation was focused upon focal occlusion of the femoral artery because 
short-segment total occlusion of the superficial femoral artery is the most common lesion 
seen with chronic obliterative atherosclerosis of the infrainguinal vessels (88).  While we 
observed the major collaterals to develop from pre-existing small arteries in our study, 
the results observed could differ significantly from what might be observed in humans 
with extensive and diffuse obstructive disease and in animal models which use multiple 
arterial ligations or excision.  While the data presented demonstrate the presence of pre-
existing collaterals in the lower extremity and hindlimb, it is important to note that other 
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 studies in various vascular beds have demonstrated that the number of pre-existing 
collaterals, as well as their ability to dilate acutely and enlarge chronically, is influenced 
by the presence of risk factors for vascular disease, physical activity, and genetic 
background (23, 89, 121, 145, 146, 162).   
In conclusion, the data presented and reviewed are consistent with the 
development of major collaterals in the hindlimb of mice, rats, and pigs and the lower 
extremity of humans from small pre-existing arteries, rather than small or terminal 
arterioles.  Except for mice, the initial size appears to be consistently >100 μm diameter.  
The enlargement most commonly observed is <3-fold.  While many recent studies have 
focused on smaller vessels and neovascularization, we consider these pre-existing small 
arteries to represent a neglected vascular segment with significant therapeutic potential in 
peripheral arterial disease.  For example, the capacity for shear-mediated luminal 
expansion in arteries is diminished or even abolished by at least some of the risk factors 
for vascular disease; specifically aging and hypertension (10, 89, 90, 145, 146).  Recent 
studies have demonstrated successful therapeutic reversal of this impairment in small 
animal models (33, 89).  Such therapies either alone or in combination with other 
molecular or cellular therapies might significantly impact the development of major 
collaterals in patients with peripheral arterial disease.  Considering that collateral growth 
is impaired in humans with risk factors for arterial disease, the development of a large 
animal model of vascular disease with impaired collateral growth would be a very 
significant addition to animal models available for preclinical testing. 
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Table 1: Hindlimb Collateral Vessel Size and Fold Enlargement 
First Author/ 
Year: 
Species Method Pathway Duration 
(Wks) 
Initial 
Size 
(μm) 
Final 
Size 
(μm) 
Fold  
Increase  
 
Neo-
Intima 
WT or 
MT 
Distasi/2008 
(39) Mouse IS GA 2 57 87 1.5* No Inc 
 Mouse IS  2-4 59 139 2.4*   
Scholz/2006 
(120) Mouse CS GA 3 42 71 1.7 No*
 Inc* 
Chalothorn/ 
2005 (24) Mouse CS GA 3 45 95 2.1* No* Inc 
(54%) 
  -Angio PA 3 75 150 2*   
Chalothorn/ 
2005 (25) Mouse CS GA 3 50 75 1.5* No* 
Inc 
(54%) 
Gruionu/ 2005 
(53) Mouse IS GA 8 20 40 2*   
Ziegelhoeffer/
2003 (167) Mouse CS GA 1 39 77 2* No* Inc* 
Scholz/2003 
(118) Mouse CS GA 1 32 49 1.5* No*  
  CS GA 4 32 77 2.4*   
Buschmann/ 
2003 (14) Mouse CS ? 2 10-30 160 5*  Inc* 
Scholz/2002 
(121) Mouse CS GA 3 36-41 76-85 2.1-2.4 No* Inc* 
Herzog/2002 
(63) Rats CC PA
 2-8 140 300 2.1* Yes Inc, 32wks 
Prior/2004 
(100) Rat IV PA 3.5 230 332 1.4*   
Scholz/2000 
(119) Rabbit CS ? 2 50 225 4.5* Yes Dec
 
    34 50 550 10*   
Longland/ 
1953 (81) Rabbit Angio Multiple 12 
100-
300 500 1.7*   
Conrad/1971 
(31) Dog CC Multiple 11 150 380 2.5*   
Buschmann/ 
2003 (14) Pig CS ? 2 10-30 620 20*   
 
Table 1: Abbreviations defined below by table column.  Method: CS = cross-sections, IS 
= in situ after vascular casting, Angio = angiogram, CC = corrosion cast, IV = isolated 
vessels (pressurized).  Pathway: GA = gracilis artery, PA = perforating artery, ? = not 
reported.  Fold Increase: * = Estimated from reported diameters.  Neointima: * = not 
reported by authors but our impression of included cross-section.  WT or MT = wall 
thickness or medial thickness, * = not reported by authors but our impression of included 
cross-section, Inc = Increased, Dec = Decreased. 
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 Figure Legends:  
Figure 1: Diagram of the hindlimb arterial vasculature and experimental model in pigs, 
rats and mice.  Sketches demonstrate the location of the arterial ligation site (X) in each 
species and identify the pre-existing vessels which form the major collaterals identified in 
this study; namely the profunda femoral and gluteal arteries in pigs, superficial 
circumflex iliac and perforating arteries in rats, and gracilis artery in mice.  SFA = 
superficial femoral artery. 
  
Figure 2: Major collaterals in human lower extremity angiograms with arterial occlusion.  
Collateral vessels are observed bypassing the site of a superficial femoral artery (SFA) 
occlusion (A), a popliteal artery (PA) occlusion (B), and a patch angioplasty combined 
with multiple SFA occlusion (C and D) in three different patients.  The occlusion(s) is 
bounded by * and differing degrees of tortuosity, which occasionally occur within the 
same collateral pathway, are indicated by arrows (less tortuous) or arrowheads (more 
tortuous).  The collaterals providing distal reconstitution arise from pre-existing, named 
arteries as labeled.  
 
Figure 3: Representative porcine hindlimb angiographic series demonstrating major 
collateral arteries.  Angiograms were reviewed frame by frame to identify true bypass 
collaterals responsible for the reconstitution of the distal superficial femoral artery (SFA) 
in each pig.  (A) Experimental limb prior to contrast injection.  (B) Appearance of the 
SFA, profunda femoral artery (PFA), and gluteal artery (GA) with contrast injection.  
Arrows in C indicate multiple sites of distal SFA filing and arrows in D identify 
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 collaterals arising from branches of the SFA, PFA, and GA.  Note that not all collaterals 
have a tortuous appearance.  Panels E and F demonstrate reconstitution of the distal SFA 
and the exit of the contrast medium from the PFA and GA; asterisks in F indicate the 
ligation site of the SFA.  (G) Angiogram of the same-animal control limb highlights the 
preexisting small arteries (identified by arrows) which form the origins of major 
collateral.  Spatial calibration is identical for all panels.  
 
Figure 4: Major collaterals in rat hindlimb with proximal femoral artery occlusion.  
Representative intravital microscopy images of vascular casting in the experimental and 
control limbs of the rat.  The superficial circumflex iliac artery (SCIA) branches from the 
femoral artery (FA) and gives rise to a proximal branch (arrowheads) that undergoes 
collateral enlargement when the femoral artery is ligated (X).  The contralateral control 
proximal branch vessel can be observed in the unligated, control limb. 
 
Figure 5: Major collaterals in mouse hindlimb with distal femoral artery occlusion.  
Representative intravital microscopy images of vascular casting in the experimental and 
control limbs of the mice.  The femoral artery (FA) ligation point is indicated, as are the 
saphenous (SA) and profunda femoral (PFA) arteries.  The major collateral pathway 
(arrowheads) involves the pre-existing gracilis artery (arrows) passing through the 
anterior gracilis muscle, which is clearly evident in the control limb.  The posterior 
gracilis artery can also contribute to collateral blood flow and is observed just below the 
arrowheads.   
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Figure 6: Cross-sections of pig, rat, and mouse control and major collateral arteries.  
(A) Comparison of control and collateral porcine arteries revealed an increase in intimal 
cell number in the collateral without apparent neointimal formation.  The same result also 
was obtained for the enlarged collaterals in rats (B) and mice (D).  For a regressing 
collateral pathway identified in the rat (C), neointimal formation (arrow) is apparent but 
not an increase in intimal cell number.  (E) images of a mouse and rat collateral are 
inserted into the lumen of a pig collateral to emphasize the tremendous difference (>10-
fold) in vessel size, wall thickness, and distance from inner to outer wall layers.  Ad = 
adventitia, M = media, L = lumen, arrowheads indicate the intima, * = denotes artifacts 
from histological processing and/or Microfil ® casting agent left in the lumen.  Control 
and collateral artery pairs from all species were imaged at the same magnification.   
 
Figure 7: Average diameters of hindlimb collateral and control arteries from (A) rats and 
(B) mice.  Diameter measurements were obtained from arterial cross sections.  In rats, the 
superficial circumflex iliac (SCI) artery was consistently larger in the experimental than 
control limb (8 of 12 rats).  Diameters of the perforating artery (PA) are divided into two 
groups depending upon whether the diameter in the experimental limb was larger (Enl-
PA, 3 of 12 rats) or smaller (Reg-PA, 9 of 12).  In mice, the gracilis artery (GA) was 
consistently enlarged in the experimental limb. 
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 CHAPTER II 
Suppressed Hindlimb Perfusion in Rac2-/- and Nox2-/- Mice  
Does Not Result from Impaired Collateral Growth 
Abstract:   
While tissue perfusion and angiogenesis subsequent to acute femoral artery 
occlusion are suppressed in Nox2-/- mice, studies have not established the role of Nox2 in 
collateral artery enlargement.  Rac2 is a small GTPase which binds Nox2 and activates 
the Nox2-based NAD(P)H oxidase, but unlike Nox2 is primarily restricted to bone 
marrow derived cells.  In this study, we utilized Rac2-/- and Nox2-/- mice with a novel 
method of identifying primary hindlimb collaterals to investigate the hypothesis that 
collateral growth requires these molecules.  When initial studies performed with femoral 
ligation demonstrated similar perfusion and collateral growth in the Rac2-/-, subsequent 
studies were performed with a more severe ischemia model, femoral artery excision.  
After femoral excision, tissue perfusion was suppressed in Rac2-/- relative to C57BL/6 
(BL6) mice.  The diameters of primary collaterals identified during Microfil® injection 
with intravital microscopy were enlarged to a similar extent in BL6 and Rac2-/- mice.  
Intimal cell number in collateral cross-sections was also increased in both strains and the 
cells were CD31 positive, CD45 negative.  Circulating leukocytes and CD11b+ cells were 
increased more in Rac2-/- than BL6.  Experiments performed in Nox2-/- mice to verify 
that the unexpected results related to collateral growth were not unique to the Rac2-/- 
gave equivalent results.  The data demonstrate that, subsequent to acute femoral artery 
excision, perfusion recovery is impaired in Rac2-/- and Nox2-/- mice but that collateral 
luminal expansion and intimal cell recruitment/proliferation are normal.  These novel 
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results indicate that collateral luminal expansion and intimal cell recruitment/proliferation 
are not mediated by Rac2 and Nox2. 
 
Key Words: arteriogenesis, macrophage, reactive oxygen species, hindlimb ischemia 
 Introduction: 
In the peripheral circulation, the dilation and enlargement of pre-existing vessels 
which form collateral pathways subsequent to arterial occlusion is the primary vascular 
compensation which preserves tissue viability and maintains function.  These vessels 
dilate within seconds (42, 71, 81, 149), and undergo expansion for weeks (31, 42, 81, 
148).  In various species, the pre-existing vessels are the size of the smallest arteries and 
they enlarge ~100% (24, 31, 63, 81, 121).  Available clinical studies indicate subsequent 
to arterial occlusion in the peripheral circulation, the primary vessels to enlarge as 
collaterals are pre-existing named arteries (8, 51, 122).  The largest of the pre-existing 
vessels are typically those which become the dominant collaterals (63, 81, 100).  
Combined anatomical and modeling studies have predicted that hindlimb flow 
subsequent to femoral artery occlusion is primarily determined by these collaterals (36, 
121).  This is consistent with studies of segmental resistances which demonstrate that 
compensation in the collateral vessels is of significantly greater hemodynamic 
importance than adaptations in the distal microvasculature (76, 150, 163).  Nevertheless, 
few studies investigating mechanisms of vascular compensation subsequent to arterial 
occlusion in mice have specifically identified and studied these pre-existing vessels 
which form the primary collateral pathways.  Such investigations are needed because 
angiogenesis and collateral growth are initiated by different stimuli, and differences exist 
in the molecules and mechanisms which mediate these important processes (13, 19).   
Leukocytes, especially lymphocytes (132, 156) and macrophages (6, 58, 67), have 
been indicated to have an important role in vascular compensation to hindlimb ischemia.  
Recent studies from Tojo et al. (140) and Urao et al. (151) have established that Nox-2 
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 derived reactive oxygen species (ROS) from bone marrow derived cells (BMDC) have an 
important role in neovascularization in the ischemic mouse hindlimb.  The initial report 
(140) concluded from suppressed blood flow that collateral growth was impaired, but did 
not specifically identify collateral bypass vessels or measure their diameters.   
In order to investigate the hypothesis that Nox2 NAD(P)H oxidase mediates 
primary collateral growth subsequent to arterial occlusion, the current study utilized Rac2 
null (-/-) and Nox2-null mice and a novel method of identifying primary hindlimb 
collaterals.  Rac2 is expressed primarily, if not exclusively, in hematopoietic cells (68, 
107), and binds to and activates the Nox2-containing NAD(P)H oxidase (38, 72).  In 
addition, leukocytes from Rac2 and Nox2 null mice have impaired function related to 
reduced ROS production (94, 140, 151).  We present a method to identify a dominant or 
primary collateral which should be the major collateral supplying flow to the distal limb 
and utilize this vessel to determine if mechanisms of collateral growth are impaired by 
Rac2 ablation.  Our results indicate that Rac2 is not required for the enlargement of these 
primary collateral arteries but is required for the recovery of hindlimb perfusion and the 
maintenance of distal tissue morphology subsequent to femoral artery ligation and 
excision.  As these results were unexpected, primary collateral artery enlargement was 
also investigated in Nox2-/- mice.  The response of Nox2-/- mice to arterial excision was 
similar to that observed in the Rac2-/- mice.  Therefore, the results obtained in the current 
study indicate that enlargement of pre-existing primary collaterals in the murine hindlimb 
occurs independently of both Rac2 and Nox2.   
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 Materials/methods: 
Animals 
Rac2-/- and Nox2-/- backcrossed into a C57BL/6J background for >12 
generations and C57BL/6J wild type (BL6) mice were studied at age 3-6 month.  Rac2-/- 
and Nox2-/- mice were bred and maintained at Indiana University while C57BL/6 were 
obtained from Harlan Industries (Indianapolis, IN).  Six BL6 and 7 Rac2-/- were used in 
the initial experiments with femoral artery ligation.  For femoral artery excision, 7 BL6, 
14 Rac2-/-, and 9 Nox2-/- were used for perfusion studies with half of the Rac2-/- and 
Nox2-/- being utilized for the morphometric and histological studies.  All animal 
procedures were approved by the Institutional Animal Care and Use Committee of the 
Indiana University School of Medicine. 
Murine Hindlimb Ischemia Model 
Animals were anesthetized via 2% isofluorane delivered under constant oxygen 
flow.  The right hindlimb was shaved, the hair was removed with a depilatory agent, and 
the area to be incised was sterilized by cleansing with iodine and an alcohol prep pad.  
The animal was then placed on a heating pad to maintain body temperature and aseptic 
surgical techniques were utilized.  An approximately 1 cm incision was made from the 
origin of the saphenous artery to the groin.  A schematic of the normal murine hindlimb 
vascular anatomy is presented in Supplemental Figure S1A.  One of two procedures was 
then performed which produced a femoral artery ligation model with moderate ischemia 
or a femoral artery excision model with more severe ischemia (128).  In the former, the 
femoral artery was carefully dissected away from the vein and nerve and ligated with 
sterile 6-0 silk suture at a point distal to the superficial epigastric artery and proximal to 
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 the femoral’s trifurcation into the saphenous, popliteal, and geniculate arteries 
(Supplemental Figure S1B).  In the excision model, an additional ligature was placed on 
the femoral artery at the level of the inguinal ligament with 6-0 silk suture, all side 
branches were ligated with 9-0 silk suture, and the femoral artery was excised 
(Supplemental Figure S1C).  The incision was then closed with sterile 5-0 resorbable 
suture and the animal was given buprinorphen 0.05 mg/kg subcutaneously for pain 
maintenance.  In all experiments, great care was taken to keep all vessels and tissues 
moist and to minimize trauma to adjacent tissue in an attempt to reduce local 
inflammation. 
Laser Doppler Perfusion Imaging 
Laser Doppler perfusion imaging (LDPI) (Model LDI-2, Moor Instruments, 
Devon, U.K.) of the hind paw plantar surface was performed over the course of 14 days 
to serially and non-invasively assess the recovery of hindlimb perfusion subsequent to 
arterial ligation/excision.  To control for temperature variation during laser Doppler 
scanning, the animal was placed on a heating pad set at 37°C as previously described (3).  
Each animal was allowed to acclimate to the heating pad/scanning environment for ≥10 
minutes before scanning was performed.  
Perfusion Fixation and Vascular Casting 
After day 14 the animal was again anesthetized, the infrarenal abdominal aorta 
was cannulated in the direction of flow with pulled PE-50 tubing, and the hindlimbs were 
perfused at a constant pressure (100 mmHg) with 10 ml of 0.9% sterile saline with dilator 
(10 mM adenosine and 1 mM Na-nitroprusside) and heparin (2.5 U/ml heparin) followed 
by 10 ml of 4% Zn-formalin.  Microfil® vascular casting agent (Flow Tech Inc., Carver, 
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 MA) was then slowly injected through the aortic cannula while monitoring the saphenous 
artery through a dissecting microscope.  The Microfil® injection was stopped as soon as 
the casting agent appeared distal to the most caudal ligation (as it entered the saphenous 
artery) and the primary collateral pathway was noted.  Some filling of the distal 
vasculature continued until pressure was equilibrated.  The carcasses were then wrapped 
in Saran Wrap® and stored at 4°C overnight prior to dissection.   
Collateral Growth and Determination of Primary Compensatory Pathways 
After the casting agent had cured, the previously identified collateral pathway was 
carefully dissected from its point of insertion to its origin.  Digital images (via a Leica 
MZ-95 microscope with Diagnostic Instruments Inc. Spot Insight Image Sample camera) 
of the in situ collateral vessel (Figure 1B) were obtained at the midzone region (81).  
Then the identical pathway was located, dissected in the contralateral control limb as in 
the ligated limb (Figure 1B), and imaged at the same location.  Vessels diameters were 
measured from the images and collateral growth was assessed by comparing diameters of 
the same animal control and collateral vessels. 
Immunophenotyping and FACS 
A HEMAVET Model 950FS cell counter (Drew Scientific Inc., Waterbury, CT) 
was used to determine the number of total white blood cells (WBCs) in blood samples 
collected from the tail vein.  To assess cell-surface antigen expression, murine peripheral 
blood mononuclear cells were incubated with primary or isotype control antibodies, as 
outlined below, in 100 μl of phosphate-buffered saline (PBS)/1% fetal bovine serum 
(FBS) (PBS, Invitrogen, Grand Island, NY; FBS, Hyclone, Logan, UT).  All incubations 
were performed at 4°C for 30 minutes; cells were washed with PBS/1% FBS and 
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 analyzed using Fluorescence Activated Cell Sorting (FACS, FACSCaliber, BD 
Immunocytometry Systems, San Jose, CA).  Primary antimouse monoclonal antibodies 
against CD11b were conjugated to phycoerythrin (PE, BD Pharmingen, San Diego, CA).  
Directly conjugated PE rat immunoglobulin G2b,κ (IG2b,κ) (BD Pharmingen) was used for 
isotype controls. 
Histology, Intimal Cell Counts, and Immunostaining 
Once the primary compensatory collateral pathways were identified in the 
adductor muscles, the control and collateral vessels as well as the more distal control and 
experimental limb gastrocnemius muscles were harvested and placed in 4% Zn-formalin 
for 24 hrs before histoprocessing.  Vessel and gastrocnemius muscle tissues were 
embedded in plastic, stained with either Hematoxylin and Eosin or Lee’s Methylene 
Blue, then visualized and imaged with 5-40X objectives on a Leica DM 5000B 
microscope with a Diagnostic Instruments Inc. Spot RTKE camera.  For immunostaining, 
sections were blocked for endogenous peroxidase activity with 3% hydrogen peroxide in 
methanol following antigen retrieval either in Antigen Unmasking Solution (Vector 
Laboratories, Berlingame, CA) at 95°C for CD45 staining or in 20 ng/ml Proteinase K for 
15 minutes at 37°C for CD31 staining.  Sections were blocked in 3% bovine serum 
albumin (BSA, Sigma) for 1 h and were stained for CD31 or CD45 (BD Pharmingen, San 
Jose, CA). Purified class- and species-matched immunoglobulins (BD Pharmingen) were 
used for isotype controls.  Sections were incubated with appropriate biotinylated 
secondary antibody (Vector Laboratories) followed by incubation with 3,3'-
Diaminobenidine (DAB, Vector Laboratories) and counterstained with hematoxylin to 
permit nuclear identification.    
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 Statistical Analysis 
Statistical analyses were performed with two way repeated measures ANOVA 
(SigmaStat 3.0).  When the ANOVA identified significant differences (P≤0.05), the 
Holm-Sidak method was used for pairwise multiple comparisons.  Data are expressed as 
means ± SEM. 
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 Results: 
Effect of Rac2 Knockout on Vascular Compensation for Femoral Arterial Ligation   
 Isolation of the primary collateral vessels revealed four different pathways.  
Representative micrographs are presented in Figure 1A and the legend contains 
additional details of each pathway.  For each collateral, an identical pathway existed in 
the contralateral control limb (Figure 1B).  The primary collateral pathway that enlarged 
most frequently in response to single arterial ligation in both Rac2-/- and BL6 mice was 
the Gracilis Collateral pathway (Table 1). 
 Hindlimb perfusion, diameters of collaterals and contralateral control arteries, 
cross-sectional intimal cell number and representative micrographs are presented in 
Figure 2.  LDPI (Figure 2A) demonstrated improved perfusion in the experimental limb 
by day 7 with no differences between BL6 and Rac2-/- at any time point.  Comparison of   
diameters (Figure 2B) indicated similar expansion of the primary collateral vessel 
diameter relative to same animal control in the Rac2-/- mice and BL6 mice (36±10.4% 
vs. 55±12.3%, respectively).  Histological assessment of the primary collateral vessels 
demonstrated a profound increase in intimal cell number in the collateral vessels versus 
their same animal controls which was similar in both strains (159±25.1% in BL6 and 
124±30.6% in Rac2-/-, Figure 2C).  Micrographs representative of all animals 
investigated in each group (Figure 2D) demonstrate the increase in collateral intimal cell 
number.  All intimal cell nuclei have a similar phenotype (size, shape, orientation) that is 
consistent with endothelial cells.  We performed immunostaining and observed the entire 
collateral intima to be CD31 positive and CD45 negative (data not shown).  This is 
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 consistent with our previous studies in rats in which the entire collateral intima is positive 
for eNOS (144) and negative for ED2 (126). 
 Micrographs of the gastrocnemius muscles after femoral artery ligation are shown 
in Supplemental Figure S2.  Minimal if any abnormalities were apparent in the 
experimental limb gastrocnemius sections of BL6 and Rac2-/- experimental limbs as 
represented in Supplemental Figure S2 B and C, respectively.   
The similarity of collateral growth between strains was unanticipated and seemed 
inconsistent with previous studies with a model of more severe ischemia (140, 151).  For 
this reason a more severe excision model was studied.  Collateral growth was evaluated 
after both 7 and 14 days to determine if the rate but not final magnitude of collateral 
growth was suppressed (139).    
Effect of Rac2 Knockout on Vascular Compensation for Femoral Arterial Excision 
 Figure 3 presents the data for hindlimb perfusion, diameters of collaterals and 
contralateral control arteries, and cross-sectional intimal cell number after femoral artery 
excision.  Analysis of the LDPI data by 2-way Repeated Measures ANOVA indicated a 
significant difference between strains (P<0.001), day (P<0.001), and a significant 
interaction (P = 0.003).  As shown in Figure 3A, LDPI was increased by day 7 in both 
BL6 and Rac2-/-.  In Rac2-/- there was an additional increase from day 7 to 14.  The 
LDPI ratio was similar between strains at day 1, but was significantly less in Rac2-/- than 
BL6 at days 7 and 14.  Consistent with the reduced perfusion observed in the Rac2-/-, 
micrographs of gastrocnemius muscles shown in Supplemental Figure S3 demonstrate 
greater tissue damage in these mice.  Comparison of the day 14 LDPI ratio indicated the 
perfusion was significantly lower in the limbs with femoral artery excision than ligation 
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 of both the Rac2-/- and BL6 mice (P≤0.001 for both strains).  Collateral growth occurred 
in both Rac2-/- and BL6 mice, as indicated by a significant increase in the collateral 
vessel diameter compared to the same animal control vessel diameter after both day 7 and 
day 14 (Figure 3B).  This collateral vessel expansion was similar between the Rac2-/- and 
BL6 mice at both day 7 (110±43.9 vs. 93±19.3, respectively) and day 14 (170±18.2 vs. 
144±22.3, respectively).  The collateral cross-sections demonstrated similar morphology 
as observed with the more moderate model; collateral intimal cell number relative to 
same animal controls was increased 129±32.0% in BL6 and 213±45.0% in Rac2-/- 
(Figure 3C).    
Assessment of Bone Marrow Derived Cell (BMDC) Response 
 In order to determine if a BMDC mobilization defect was present in the Rac2-/- 
mice, circulating cell counts of total white blood cells (WBCs) and CD11b+ cells, which 
have been previously shown to mediate improved perfusion in the mouse hindlimb (18), 
were performed via HEMAVET and FACS analysis.  Figure 4 demonstrates there were 
significantly more total WBCs (Figure 4A) and CD11b+ (Figure 4B) cells circulating in 
the bloodstream of Rac2-/- mice.  In addition, WBCs were increased at day 3 in BL6 and 
Rac2-/- mice and remained elevated in Rac2-/- animals.  CD11b+ cells were increased at 
days 3 and 7 only in Rac2-/- mice.  This may indicate either an increased production/ 
release of BMDCs in the Rac2-/- mice (1) or a decreased ability of the Rac2-/- 
monocytes/macrophages to migrate from the bloodstream into the distal tissues.   
Effect of Nox2 Knockout on Vascular Compensation to Femoral Artery Excision 
Our observation of normal collateral growth in the Rac2-/- mice was again the 
opposite of what we had anticipated based upon previous studies in Nox2-/- mice.  Since 
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 Rac2 ablation may have effects not mediated through the binding and activation of the 
Nox2 NAD(P)H oxidase, we performed additional experiments in Nox2-/- mice with 
femoral artery excision to determine if the phenotype we had observed was unique to the 
Rac2-/- mice. 
Hindlimb perfusion, collateral growth, and typical skeletal muscle histology 
observed after femoral artery excision in the Nox2-/- mice are reported in Figure 5 and 
Supplemental Figure S4.  The pattern of hindlimb perfusion (Figure 5A) was similar to 
that of the Rac2-/- mice with limited recovery at day 7.  Very significant collateral 
growth occurred in the Nox2-/- mice, as indicated by the greater collateral diameter 
compared to the same animal control vessel diameter at day 14 (Figure 5B).  The 
collateral blood vessel enlargement in the Nox2-/- mice relative to same animal control 
(158±36.3%) was similar to that observed in Rac2-/- and BL6 mice.  Collateral intimal 
cell number increased and lipid deposition occurred in the Nox2-/- experimental limbs 
similar to that observed in the Rac2-/- mice (Supplemental Figure S4).   
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 Discussion: 
Novel and significant aspects of the current study include: 1) the presentation of 
an improved method of identifying primary collaterals in the mouse hindlimb for the 
assessment of collateral artery growth, 2) an increase in intimal cell number in the 
primary collaterals of Rac2-/- and BL6 mice consistent with elevated shear, 3) greater 
leukocyte mobilization in Rac2-/- mice than BL6 after femoral artery excision, and 4) 
normal enlargement of primary collaterals in Rac2-/- and Nox2-/- mice despite impaired 
tissue perfusion and increased skeletal muscle injury in the distal limb.   
Assessment of Collateral Growth 
While many previous studies have compared diameters of specific vessels in the 
mouse hindlimb to assess collateral growth (16, 23, 24, 53, 97, 120, 121), the method 
presented in this study provides a number of advantages.  Controlled perfusion fixation 
with dilator preserves the vasculature in a consistent state.  Slow injection of vascular 
casting material during microscopic observation helps ensure reliable filling, permits 
identification of the first vessels through which the casting agent enters the distal 
vasculature, and facilitates dissection of the collateral pathway for diameter 
measurement.  With this method we established that four primary pre-existing collateral 
pathways exist in the hindlimb (Figure 1).  The fact that these pathways are the first to 
provide casting material to the distal vasculature suggests that they are the pathways of 
least resistance and represent the dominant or primary collaterals.  These are the vessels 
which others have concluded are primarily responsible for distal limb perfusion (36, 121).   
This is similar to the clinical situation as the major collaterals in the lower extremity are 
identified as pre-existing named arteries (37, 41, 51, 78, 122).  We also demonstrated that 
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 the primary pathway varies not only between models, but even among different animals 
within the same model (Figure 1, Table 1).  Similar variation in the collateral pathway 
exhibiting the greatest luminal expansion also occurs in the rat hindlimb, based upon 
comparison of angiograms in existing studies (63, 100) and our preliminary observations.  
Because of this variation, failure to identify the primary collateral pathway(s) can result 
in significant underestimation of collateral growth.  The identification of primary 
collaterals and their isolation permits the investigation to be performed at the vessel/local 
tissue level where stimuli and structural and molecular remodeling should be more 
uniform than the isolation of whole muscle sections such as adductors which could 
contain not only enlarging collaterals but also static and even regressing vessels.   
Intimal Response in Primary Collaterals 
In the primary hindlimb collaterals of BL6, Rac2-/-, and Nox2-/- mice, we 
observed a profound increase in intimal cell number (Figures 2C, 3C, S4).  This response 
was uniform along the circumference and, unlike previous reports (63, 119), did not 
involve apparent neointimal formation.  To our knowledge, this is the first report of such 
an intimal response in mouse hindlimb collaterals and it was typical of all primary 
collaterals we observed.  The intimal cells were CD31 positive and CD45 negative 
indicating they are endothelial rather than myeloid or epithelial cells (65).  In preliminary 
studies we have observed equivalent responses in primary collaterals in the rat and pig 
hindlimb.  This intimal response is similar to that observed prior to luminal expansion in 
carotid arteries (83, 129) and small mesenteric arteries subjected to chronically elevated 
flow (126, 144, 146, 148).  Such an increase in intimal cell number can be explained by 
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 endothelial cell proliferation/recruitment (126, 129, 144) and is suppressed in collateral 
vessels which do not enlarge (126, 146). 
Role of Bone Marrow Derived Cells 
Tissue resident progenitor and bone marrow derived cells have been shown to be 
critically important in vascular and skeletal muscle adaptations subsequent to femoral 
artery occlusion.  Available studies indicate that both Rac2 and Nox2 null mice have 
major defects in BMDC function including ROS production, homing, and chemotaxis 
(94, 107, 151, 152).  Indeed, bone marrow cell transplantation studies performed by Urao 
et al. (151) provide compelling evidence that the effects of Nox2 on perfusion and 
capillary density in the ischemic hindlimb are mediated by bone marrow-derived cells.  
Skeletal muscle fat accumulation, as observed in the micrographs of Rac2-/- and Nox2-/- 
mice after arterial excision (Supplemental Figures S3 and S4), has been associated with 
an impaired inflammatory cell response (32).  Yet, in spite of this, collateral luminal 
expansion and intimal cell proliferation/recruitment were not impaired in the Rac2-/- or 
Nox2-/- mice.  The simplest interpretation of the data is that the growth of primary 
collaterals is not mediated by Rac2 or Nox2.  
Vascular Compensation to Arterial Occlusion 
Tissue perfusion assessed by LDPI increased significantly in all animals after day 
1.  Relative to BL6, this increase was suppressed in Rac2-/- and Nox2-/- mice with 
femoral artery excision (Figures 3A and 5A).  The reduced perfusion is consistent with 
the increased lower limb injury (Supplemental Figures S3 and S4) observed in the Rac2   
-/- and Nox2-/- and previous reports in the hindlimb of Nox2 null mice (140, 151).  
Subsequent to femoral artery ligation, the perfusion of the distal tissues is determined by 
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 the vascular resistance of the bypass collaterals and the distal microcirculation (76, 150, 
163).  The majority of the vascular resistance distal to the occlusion is in the bypass 
collateral vessels (76, 150, 163).  As compensation occurs and perfusion is increased, the 
major decrease in resistance occurs in the collaterals with minimal if any decrease in 
distal microvascular resistance (76, 150, 163).  Comparable studies after femoral artery 
excision are not available, but we would expect that the collateral resistance would be 
even greater with femoral artery excision.  Based upon this reasoning, we were surprised 
that perfusion was compromised in the Rac2 and Nox2 null mice when the growth of 
primary collaterals was not suppressed.  Potential explanations include abnormal 
collateral function, impaired growth of smaller collaterals, or microvascular 
abnormalities.  This work was focused on collateral growth assessed by luminal 
expansion and did not assess collateral tone or the ability of the enlarged collaterals to 
dilate and constrict.  Functional differences in the collaterals could result in a perfusion 
deficit.  While it is possible that there could be a difference in the number of enlarging 
collaterals, the similar enlargement of the major collaterals suggests that the mechanisms 
responsible for collateral growth are not impaired.  Previous studies in the Nox2-/- mouse 
have shown clear impairment of angiogenesis, but capillaries comprise such a small 
component of skeletal muscle microvascular resistance (7, 49) that it is not clear that the 
difference in perfusion between hindlimbs of BL6 and Rac2 and Nox2 null mice after 
femoral excision can be attributed to differences in capillarity.  Other studies have shown 
that perfusion subsequent to femoral artery occlusion is not correlated with capillarity 
(62, 121).  Studies have shown that chronic reductions in flow and pressure can result in 
enhanced constriction and inward remodeling characterized by wall thinning (5, 9, 15, 28, 
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 30, 73, 98, 99, 133, 144); characteristics which occur in human critical limb ischemia 
(28-30).  Thus, the profound decrease in distal microvascular flow and pressure could 
result in similar decompensatory events in the precapillary arterioles and small arteries 
which control the majority of microvascular resistance (7, 49, 75, 169).  Such a 
decompensatory response could be exaggerated in the Rac2 and Nox2 null mice.  
Certainly more work is warranted to identify the specific vascular segment and 
mechanisms responsible for the reduced perfusion observed with severe ischemia in the 
Rac2 and Nox2 null mice. 
In conclusion, Rac2 and Nox2 null mice were utilized with a novel method of 
identifying primary hindlimb collaterals to investigate the hypothesis that the growth of 
primary collaterals subsequent to arterial occlusion is mediated by Rac2 and Nox2.  
Results obtained suggest that enlargement of pre-existing primary collaterals in the 
murine hindlimb is independent of both endothelial and leukocyte Nox2.  Since collateral 
growth is modulated if not mediated by elevated flow (45, 96), this interpretation is 
consistent with the observation that p47phox but not Nox2 mediates flow-induced outward 
remodeling (21).  These results provide further evidence that different stimuli initiate 
angiogenesis and collateral growth and that differences exist in the molecules and 
mechanisms that mediate these important processes.  Additional studies are warranted to 
clarify how the pre-capillary microcirculation is influenced by Rac2 and Nox2 in 
hindlimb ischemia and how the presence of vascular disease and risk factors alter Nox2 
dependent compensation. 
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Table 1: Summary of the Primary Collateral Pathway Locations 
 BL6  
Ligation 
Rac2-/-  
Ligation 
BL6  
Excision 
Rac2-/-  
Excision 
Nox2-/-  
Excision 
Gracilis Collateral 12 (100%) 9 (82%) 7 (50%) 2 (22%) 4 (80%) 
Deep Adductor 2 (17%) 1 (9%) 3 (21%) 3 (33%) 1 (20%) 
Middle Dorsal 1 (8%) 0 3 (21%) 0 1 (20%) 
Superficial Dorsal 1 (8%) 3 (27%) 7 (50%) 5 (56%) 2 (40%) 
Sciatic Nerve Comp 0 0 1 (7%) 0 0 
# Animals with 
Multiple Paths: 3 (25%) 1 (9%) 6 (43%) 1 (11%) 3 (60%) 
Total # of Animals: 12 11 14 9 5 
 
Table 1: The number of mice having primary collaterals in the specific pre-existing 
pathway is indicated as well as percent of total in parentheses.   The counts were made 
after perfusion fixation and Microfil injection 14 days after femoral artery ligation/ 
excision.  The Gracilis Collateral pathway is the primary pathway that enlarges in 
response to femoral arterial ligation in both BL6 and Rac2-/- mice while both Adductor 
(including gracilis) and Dorsal pathways contribute equally in response to femoral 
arterial excision in both strains of mice.  In one instance, the companion artery to the 
Sciatic Nerve appeared to be the primary compensating collateral pathway. 
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 Figure Legends: 
Figure 1: Primary collateral pathways in the mouse hindlimb after 14 days of femoral 
artery ligation or excision.  (A) Intravital microscopy and Microfil® vascular casting in 
the experimental limbs of BL6 and Rac2-/- mice identified four primary pathways that 
provided a collateral bypass.  The first pathway identified was the Gracilis Collateral 
artery(s) (24), which originates from the profunda femoral (aka. muscular branch) artery 
and passes primarily through the superficial anterior and posterior gracilis muscles of the 
adductor region of the thigh to re-insert into the distal saphenous artery.  This collateral 
path has been previously described in several studies (25, 26, 53, 58, 79, 121).  The Deep 
Adductor pathway originates as a branch of the internal iliac artery, passes along the 
ventral portion of the pelvis, and then penetrates the deeper adductor musculature to re-
insert into the saphenous artery proximal to the re-insertion point of the Gracilis 
Collateral path.  This path can occasionally come off the profunda femoral artery to 
penetrate the deeper adductor musculature before re-inserting into the saphenous artery, 
as described by Scholz et al. (121).  The Middle Dorsal path originates from a different 
branch of the internal iliac than the Deep Adductor path (a branch that passes through the 
pelvis), then passes down the dorsal surface of the back to the lower limb where it 
invades the deeper adductor musculature to re-insert into the popliteal artery and may be 
evident in the angiograms of Heil et al. (58).  The Superficial Dorsal path originates from 
the same internal iliac arterial branch as the Middle Dorsal path, but upon reaching the 
lower limb it passes along the dorsal surface of the adductor musculature just underneath 
the skin (instead of penetrating the adductor muscles) to re-insert into the popliteal artery 
at a point distal to the re-insertion of the Middle Dorsal path.  This path has been 
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 observed in the angiograms of Bergmann et al. (6) as well as Shireman and Quinones 
(128).  (B) For all collateral pathways in the experimental limbs, an identical pathway 
composed of the same pre-existing vessels could be identified in the contralateral control 
limbs of the same animal (identified by arrowheads), as shown in the upper left versus 
right panels.  Diameter measurements were made from high magnification digital images 
of the collateral and control vessels (lower left and right panels, respectively).  Insets 
indicate areas enlarged in bottom panels.  FA = Femoral artery, PF = Profunda Femoral 
artery, P = Popliteal artery, S = Saphenous artery, II = Internal Iliac artery branch, 
Arrows = Collateral pathway. 
 
Figure 2: Vascular compensation to femoral arterial ligation in BL6 and Rac2-/- mice.  
(A) The perfusion of the experimental limb in BL6 and Rac2-/- mice assessed by LDPI is 
expressed relative to same animal control at days 1, 7, and 14 post-ligation.  In both BL6 
and Rac2-/-, the LDPI increased after day 1.  Perfusion ratios were similar between 
strains at all days, (BL6, n = 6; Rac2-/-, n = 7).  (B) Assessment of control and collateral 
artery diameters 14 days after femoral arterial ligation in BL6 and Rac2-/- mice indicated 
a significant increase in collateral vessel diameter vs. same animal control vessel 
diameter (BL6, n = 6; Rac2-/-, n = 7).  (C) Quantification of intimal cell number in BL6 
and Rac2-/- obtained from micrographs of control and collateral cross-sections, as 
illustrated in panel D, demonstrates an increase of >100% (BL6, n = 6; Rac2-/-, n = 7).  
(D) Vessel cross-sections (stained w/ Lee’s Methylene Blue) from BL6 and Rac2-/- mice 
14 days post-ligation demonstrate typical luminal expansion and increased intimal cell 
numbers (micrographs representative of all observed in each animal strain).  Arrows 
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 identify some of the intimal cell nuclei and * identifies Microfil in the lumen of the 
vessels, which is sometimes lost during sectioning (lower right panel).   
 
Figure 3: Vascular compensation to femoral arterial excision in BL6 and Rac2-/- mice.   
(A) LDPI perfusion ratios demonstrate an increase in perfusion by day 7 that is greater in 
BL6 than Rac2-/- mice (BL6, n = 7; Rac2-/-, n = 14).  (B) Relative to same animal 
controls, collateral diameter in BL6 and Rac2-/- mice was similarly increased at 7 and 14 
days after arterial excision (BL6, n = 6 after 7 days and n = 8 after 14 days; Rac2-/-, n = 4 
after 7 days and n = 5 after 14 days).  (C) Quantification of intimal cell number after 14 
days of femoral excision indicates a significant increase in collaterals relative to same 
animal controls of both BL6 and Rac2-/- (BL6, n = 5; Rac2-/-, n = 5). 
 
Figure 4: HEMAVET and FACS analysis of total white blood cells (WBCs) (A) and 
CD11b+ cells (B).  There were significantly more total WBC and CD11b+ cells in Rac2-/- 
than BL6 both before surgery and during the 14 days following femoral artery excision.  
The number of WBC was increased from baseline at day 3 in BL6 and day 3-14 in Rac2  
-/-.  The number of CD11b+ cells was increased from baseline at days 1 and 3 post-
ligation in Rac2-/- but not in BL6.  (BL6, n = 7; Rac2-/-, n = 6). 
  
Figure 5: Vascular compensation to femoral arterial excision in Nox2-/- mice.  (A) LDPI 
perfusion ratios for Nox2-/- mice (n = 9).  (B) Enlargement of the primary collateral 
vessel diameter occurred in the Nox2-/- and the percent increase from control is similar to 
the increase observed in both the BL6 and Rac2-/- mice (n = 5).  
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Table S1: Laser Doppler Flux Values in Control and Experimental Limbs in All 
Groups 
 Raw Day 1 Day 7 Day 14 
  Control Experimental Control Experimental Control Experimental 
BL6 
Moderate 1091.2±71.5 344.1±78.8 1227.8±57.7 888.2±78.1 1298.7±10.5 1092.7±35.5 
Rac2 -/-
Moderate 1259.8±46.0 436.8±110.2 1294.7±24.7 827.8±105.4 1251.5±35.1 806.8±95.2 
BL6 
Severe 1066.0±23.4 194.4±13.3 1078.7±41.4 585.9±62.6 1112.0±39.6 540.2±35.6 
Rac2 -/-
Severe 1222.2±133.5 168.6±20.8 1338.1±142.5 361.5±40.6 1586.4±192.1 628.2±128.7 
Nox2-/- 
Severe 992.2±28.8 223.9±22.5 893.6±29.2 283.2±26.3 964.1±31.8 424.6±62.3 
(Relative Units, Average ± SEM) 
 
Table S1: The average Laser Doppler flux units are reported.  The values from individual 
animals were used to calculate the ratios reported in Figures 1, 3, and 5. 
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 Supplemental Figure Legends: 
 Supplemental Figure S1: Schematic of the murine hindlimb vascular anatomy (A) as 
well as the femoral artery ligation (B) and excision (C) models used in this study.  EI = 
External Iliac artery, II = Internal Iliac artery, IL = Inguinal Ligament, FA = Femoral 
artery, PF = Profunda Femoral artery, SEA = Superficial Epigastric artery, P = Popliteal 
artery, S = Saphenous artery, Tortuous Line = Collateral pathway, X = Ligation site, 
Dotted red line indicates excised portion of femoral artery, Dashed red line indicates 
unspecified portion of collateral pathway connecting the internal iliac artery to the dorsal 
collateral artery. 
 
Supplemental Figure S2: Control and experimental limb gastrocnemius muscles from 
BL6 and Rac2-/- mice after 14 days of femoral arterial ligation.  The BL6 control limb 
gastrocnemius muscle in panel A is representative of all control gastrocnemius muscles 
observed in both animal strains.  The BL6 experimental limb gastrocnemius muscle in 
panel B and the Rac2-/- experimental limb gastrocnemius muscle in panel C are 
representative of those observed in both strains, respectively, and demonstrate little, if 
any, lipid deposition relative to their respective controls.  A band of connective tissue is 
seen spanning from the upper left to lower right corners of panel C.  (BL6, n = 6; Rac2-/-, 
n = 7). 
 
Supplemental Figure S3: Control and experimental limb gastrocnemius muscles from 
BL6 and Rac2-/- mice after 14 days of femoral arterial excision.  The BL6 control 
gastrocnemius muscle in panel A is representative of all control gastrocnemius muscles 
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 observed in both animal strains.  The BL6 experimental gastrocnemius muscle in panel B 
exhibited the greatest amount of lipid accumulation observed in all of the BL6.  Panel C 
is a representative micrograph of the Rac2-/- experimental limb gastrocnemius muscles 
and demonstrates the extensive lipid accumulation evident in the Rac2-/- mice.  The lipid 
deposition in B and C results from adipocyte formation (32).  Arrows indicate 
representative adipocytes characterized by the clustered, clear circular structures.  (BL6, 
n = 5; Rac2-/-, n = 6). 
 
Supplemental Figure S4: Representative control and collateral vessels as well as control 
and experimental limb gastrocnemius muscle micrographs from Nox2-/- mice. 
 Arrowheads in vessel sections identify intimal cell nuclei, * indicates Microfil® in the 
lumen of the vessels, and arrows indicate representative adipocytes responsible for the 
extensive lipid accumulation that occurred in Nox2-/- experimental limb gastrocnemius 
muscles (similar to the Rac2-/- mice, n = 3). 
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  CHAPTER III 
Pilot Study for Future Experiments: 
Effect of Bone Marrow Cell and Antioxidant Therapy  
on Age-Related Collateral Growth Impairment 
Introduction: 
Collateral growth has been shown to be impaired in the presence of risk factors 
for cardiovascular disease, as reviewed by van Oostrom et al. (153).  Specifically, 
collateral growth is impaired with aging in both humans (93) and rodents (106, 145); 
however, the mechanism mediating this impairment is unknown.  The current prevailing 
paradigm suggests that collateral growth is mediated by both the increased shear stress 
experienced in the vessels bypassing the parent artery occlusion as well as through the 
recruitment, incorporation, and subsequent growth factor production by bone marrow 
derived monocytes (12). 
Capoccia et al. recently demonstrated that injection of bone marrow cells (BMCs) 
enhances hindlimb perfusion and angiogenesis in mice; but their study did not directly 
assess collateral growth (18).  While Capoccia et al.’s study and others have 
demonstrated improvements in hindlimb reperfusion and/or angiogenesis via BMC 
therapy, the majority of these studies have been performed in young healthy animals 
experiencing an acute, surgically induced arterial occlusion.  Conversely, arterial 
occlusion in patients happens gradually over time and in the presence of significantly 
diseased vasculature.  In addition, many of the clinical trials aimed at enhancing 
angiogenesis in patients with peripheral arterial disease (PAD) in order to increase 
perfusion have failed to show a significant degree of improvement.  One reason for this 
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 discrepancy is probably due to the presence of significant vascular disease and other co-
morbidities (such as diabetes, hypercholesterolemia, etc.) in the aged patients treated in 
these trials that was absent in the young healthy animals utilized in the pre-clinical 
studies (131).  Indeed, if the field of therapeutic interventions aimed at enhancing 
collateral growth is to advance, then translational studies in appropriate animal models 
are necessary to develop and assess the potential of such interventions (159). 
Previous studies in our laboratory demonstrated that mesenteric collateral growth 
is impaired with age (145).  However, this study in aged rats did not investigate hindlimb 
collaterals (145) and a previous study in mice demonstrating an age-related impairment in 
hindlimb reperfusion focused primarily on angiogenesis (capillary proliferation), not 
adequately assessing hindlimb collateral growth (106).  Studies in rats have shown that 
~70-80% of total limb resistance in the rodent hindlimb (upon acute femoral artery 
ligation) is mediated by the bypass collateral arteries (76, 150, 163).  Thus, collateral 
growth is the primary means to compensate for a peripheral arterial occlusion.  
One possible mechanism for the age-related impairment in collateral growth is 
that the BMCs of the aged animals are unable to mediate collateral growth.  Since 
monocyte recruitment is believed to be an essential step in the mechanism mediating 
collateral growth (12), and because injection of young BMCs led to increased hindlimb 
perfusion after femoral arterial ligation in young healthy animals (18), these data suggest 
that the injection of young BMCs into aged mice may enhance hindlimb collateral 
growth.  Furthermore, Edelberg et al. (43) demonstrated transplantation of young bone 
marrow-derived endothelial progenitor cells (EPCs) into aged mice improved cardiac 
allograft viability and Heiss et al. (59) has shown age-related endothelial dysfunction to 
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 be accompanied by functional impairments in EPC proliferative activity and migratory 
response.  In addition, many studies have suggested this age-related endothelial 
dysfunction is associated with increased oxidative stress.  For example, Mayhan et al. 
(85) recently published data suggesting the impairment in eNOS-dependant cerebral 
arteriole reactivity observed with aging is due to an increased production of superoxide 
from activated NAD(P)H oxidase.  Thus, another potential mechanism for the age-related 
impairment in collateral growth could be due to the increased reactive oxygen species 
(ROS) known to be present with advancing age (35) altering the functional capacity of 
the endothelial cells, BMCs, or EPCs to mediate collateral growth.  Indeed, previous 
studies in our lab have shown ROS to be implicated in the impairment of collateral 
growth in the spontaneously hypertensive rat (SHR) (89, 166).   
Therefore, the primary objectives of this pilot study were to evaluate a mouse 
model of aging for impaired collateral growth in the hindlimb and, once this impairment 
has been established, determine if the impairment can be reversed by BMC-injection or 
antioxidant therapy.  We hypothesize that: there will be an age-related impairment of 
collateral growth in the mouse hindlimb, the injection of young BMCs into aged mice 
will enhance hindlimb collateral growth, ROS balance will be associated with the age-
related impairment of collateral growth, and that the age-related impairment of collateral 
growth in the mouse hindlimb will be characteristically similar to the age-related 
impairment of collateral growth in the rat mesentery. 
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 Materials and Methods: 
Animals 
Male C57BL/6J mice were studied at 3 (young) and 18 (old) months of age.  Mice 
were obtained from the NIA colony maintained by Harlan Industries (Indianapolis, IN) 
and housed at Indiana University.  All animal procedures were approved by the 
Institutional Animal Care and Use Committee of the Indiana University School of 
Medicine. 
Murine Hindlimb Ischemia Model 
The same procedure as outlined in Chapter II for moderate femoral arterial 
ligation was performed in all animals in this study. 
Laser Doppler Perfusion Imaging 
Laser Doppler perfusion imaging (LDPI) (Model LDI-2, Moor Instruments, 
Devon, U.K.) of the plantar surface of the hind paws was measured over the course of 14 
days as outlined in Chapter II.  In some animals, LDPI was continued for an additional 14 
days following bone marrow-derived cell injection.  Perfusion was calculated and 
expressed as the flux ratio between the non-ischemic and ischemic limbs.   
Collateral Growth Assessment and Determination of Primary Compensatory Pathways 
Perfusion fixation, vascular casting, collateral growth assessment, and 
determination of primary compensatory collateral pathways were all performed as 
outlined in Chapter II. 
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 Immunophenotyping and FACS 
  HEMAVET and FACS quantification of total circulating white blood cells 
(WBCs) and CD11b+ cells in blood samples collected from the mouse tail vein is the 
same as was previously outlined in Chapter II. 
Bone Marrow Cell Isolation and Injection 
To obtain donor cells, C57BL/6 mice 3 or 18 months old were euthanized by CO2 
inhalation and pinned in the supine position to a sterilized dissecting tray.  The hind limbs 
were removed and placed in minimal essential medium plus Earle’s salts (MEM) (Gibco, 
Grand Island, NY).  Adipose and muscle tissue were carefully removed and discarded.  
Bone marrow (BM) was flushed with MEM from the medullary cavities of tibias and 
femurs using a 27-gauge needle.  BM MNCs were obtained by Ficoll density gradient 
centrifugation.  Briefly, BM was diluted 1:1 with phosphate-buffered saline (PBS, 
Invitrogen, Grand Island, NY) and an equivalent volume of Ficoll-Paque™ PLUS (GE 
Healthcare Biosciences Corporation, Princeton, NJ) was then underlaid.  Cells were 
centrifuged for 30 minutes at room temperature at 740 x g.  MNCs were isolated and 
washed 2 times with PBS supplemented with 2% fetal bovine serum (Hyclone, Logan, 
UT), 1% penicillin/streptomycin (Invitrogen) and 0.25 µg/ml amphotericin B 
(Invitrogen).  Cell count and viability was assessed by Trypan blue (Sigma, St. Louis, 
MO) staining.  5 x 106 BM MNCs re-suspended in 200 µl of PBS, or PBS alone, were 
injected into the lateral tail vein either 24 hrs or 14 days after surgical induction of hind-
limb ischemia. 
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 Apocynin Therapy 
Starting one week before surgical ligation, animals were given a continuous dose 
of 1 mM apocynin via their drinking water (water was changed ~1-2 times a week) 
throughout the duration of their 28 day recovery period. 
Histology and Intimal Cell Counts 
Vessel tissues were embedded in plastic, sectioned, stained with either 
Hematoxylin and Eosin or Lee’s Methylene Blue, then visualized and imaged with 5-40X 
objectives (Leica DM 5000B with Diagnostic Instruments Inc. Model 7.4 Slider, 
Spot RTKE camera) as described in detail in Chapter II. 
Statistical Analysis 
Prior to statistical analysis, any values >1.5 standard deviations from the mean 
were excluded.  ANOVA was then performed with SigmaStat 3.0 to evaluate all data.  
The Holm-Sidak method was used for pairwise multiple comparisons.  Data are 
expressed as means ± SEM. 
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 Results: 
Recovery of Hindlimb Perfusion 
 As can be seen in Figure 1, Laser Doppler perfusion imaging (LDPI) 
demonstrated a significant recovery of hindlimb perfusion from the baseline established 
at Day 1 post-ligation over the course of 14 days in both young and old mice (P≤0.001 
for young and old vs. day 1); however, hindlimb perfusion was significantly greater in the 
young than in the old at all time points (P≤0.016 at day 1, P≤0.001 at day 7 and day 14 
vs. old).   
 After verification of a post-ligation perfusion impairment through 14 days, either 
bone marrow-derived mononuclear cells (BM-MNCs) obtained from young or old mice 
suspended in PBS or a PBS-only control were injected into old mice via the tail vein and 
LDPI was assessed over the course of an additional 14 days (i.e., measurements were 
made at days 21 and 28 post-ligation).  As can be seen in Figure 2, treatment of aged 
mice with either young or old BM-MNCs did not result in a significant increase in the 
hindlimb perfusion at either day 21 or day 28 post-ligation versus that observed at day 14 
in the untreated aged animals (P = 0.133 and P = 0.097 for young and old BM-MNC 
injections, respectively).  However, the hindlimb perfusion ratios at days 21 and 28 post-
ligation in aged mice following PBS-only injection were significantly increased versus 
untreated aged mice at day 14 (P≤0.001, Figure 2).  Because these results were 
unexpected we evaluated injection of BM-MNCs at day 1 post-ligation.  As can be seen 
in Figure 3, injection of young BM-MNCs at day 1 post-ligation did not result in a 
significant enhancement of hindlimb perfusion versus old untreated mice at any time 
point from day 7 through day 28 post-ligation (P = 0.126).   
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  Lastly, as recent studies have suggested collateral growth and hindlimb perfusion 
recovery are associated with a specific balance of reactive oxygen species (ROS) (108, 
140, 151), and since ROS are known to be increased with age (35), we assessed the 
recovery of hindlimb perfusion in aged mice pre-treated with the antioxidant apocynin.  
As can be seen in Figure 4, apocynin therapy in the aged mice produced a significant 
increase in the hindlimb perfusion at day 14 post-ligation (P≤0.001 vs. untreated aged 
mice at day 14).  However, this enhanced perfusion was lost by day 21 post-ligation, 
since the hindlimb perfusion ratios of the treated animals at days 21 and 28 post-ligation 
were not significantly different from untreated aged mice at day 14 (P = 0.355, Figure 4).    
 As these results were also unexpected, we questioned whether or not recovery of 
hindlimb perfusion had actually plateaued by day 14 post-ligation, or if it was possibly 
still fluctuating between days 14 and 28 post-ligation.  Therefore, a second group of 
young and old mice that remained untreated throughout the entire 28 day post-surgery 
recovery period were evaluated.  Unfortunately, Figure 5 demonstrates that this second 
(2nd) group of young and old mice gave us completely different hindlimb perfusion 
recovery profiles than the initial group of young and old animals we assessed.  Similar to 
our initial group, the 2nd group of young mice showed significant perfusion recovery by 
day 14 (P≤0.001 vs. young day 1).  The 2nd group of old mice eventually showed 
significant recovery as well (P≤0.001 vs. old day 1); however, the recovery in the 2nd old 
mice did not occur until day 21 while it had already reached significance by day 14 in the 
initial group.  Most importantly, and in contrast to the initial group which showed a 
significant difference in hindlimb perfusion between young and old mice at all time 
points, there was no significant difference in the hindlimb perfusion ratios between the 
 100
 young and old mice at any time point in the 2nd group (at day 14, P = 0.004 but the 
confidence interval of the analysis was 0.002; at all other time points, P≥0.188).   
Growth of Primary Collateral Vessels 
 As can be seen in Figure 6, young mice exhibited a significantly greater degree of 
enlargement in their primary collateral vessels than did the aged mice 14 days after 
arterial ligation, indicated by a significantly larger percent increase of collateral vessel 
diameter in the young versus old (55±8.2% vs. 14±9.7%, respectively, P≤0.011).  This 
finding is consistent with the increased perfusion observed in the young versus the old 
mice at Day 14 post-ligation shown in Figure 1.  However, Figure 6 also demonstrates 
both young and old mice exhibited the same degree of collateral vessel enlargement by 
28 days post-ligation (102±18% vs. 99±29%, respectively).  This finding is consistent 
with the similar perfusion observed in the young versus the old mice at Day 28 post-
ligation shown in Figure 5.  Therefore, the aged mice do not demonstrate a complete lack 
of collateral growth capacity, but instead have a delayed ability to develop collateral 
vessels in response to femoral arterial ligation.   
 Ligations were created in additional aged mice and these animals were then 
treated with either a PBS-only control injection (iv.), an injection of BM-MNCs on day 1 
or day 14 post-ligation, or pre-treated with apocynin, and then sacrificed 28 days after 
surgical induction of collateral development.  Table 1 demonstrates that neither injection 
of BM-MNCs (at either day 1 or day 14 post-ligation) nor apocynin pretreatment resulted 
in an enhanced capacity for collateral development, since there was not a significant 
increase in the percent of collateral enlargement in any of the treatment groups versus the 
untreated aged mice at 28 days post-ligation (Table 1).  In fact, injection of young BM-
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 MNCs at day 1 post-ligation significantly reduced the percent increase in collateral 
diameter that should have occurred by day 28 post-occlusion (P≤0.001, Table 1).  Again, 
these results were contrary to our expectation that either BM-MNC injection or 
antioxidant treatment would significantly enhance collateral development in aged mice. 
Assessment of Bone Marrow Derived Cell (BMDC) Response 
 Since white blood cells (WBCs) in general, and CD11b+ WBCs in particular, have 
been previously shown to mediate improved perfusion in the mouse hindlimb (18), the 
number of circulating white blood cells (WBCs) and CD11b+ cells was determined in 
untreated young and old mice via HEMAVET and FACS analysis (respectively) to 
investigate whether a defect in the number of circulating BMDCs was present in the aged 
mice.  Figure 7 demonstrates that, while there are no significant differences in the number 
of total WBCs between young and old mice (Figure 7A), the old mice start out with a 
significantly higher number of CD11b+ cells circulating in the bloodstream than do the 
young mice (P≤0.008, Figure 7B).  However, this difference is lost between days 3 and 7 
post-ligation.  This sharp decline in the number of circulating CD11b+ cells in the aged 
animals could indicate that these cells are leaving the bloodstream and migrating into the 
tissues, possibly to effect collateral growth.  Previous studies have shown that 
monocyte/macrophage accumulation around growing collateral vessels in young healthy 
animals is maximal three days post-occlusion (119).  In the current study, this emigration 
of monocytes in young mice from the bloodstream could be indicated by the slight 
decrease in circulating number of CD11b+ observed between Days 1 and 3 post-ligation 
in Figure 7B.  Thus, if these cells are the necessary prerequisite of collateral growth, the 
sharp decline in CD11b+ cells between Days 3 and 7 post-ligation in the old mice (Figure 
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 7B) would be consistent with the delay in collateral growth suggested by the LDPI and 
diameter data (Figures 5 and 6, respectively).  However, additional experiments are 
needed to determine where these CD11b+ cells are going and whether or not they are 
truly effecting collateral growth.  It can be concluded from the current data that there is 
no defect in the number of circulating BMDCs in the aged mice versus young; indeed, 
there were significantly more CD11b+ cells at baseline in the aged mice than in the 
young. 
Histological Assessment of Primary Collaterals   
 Histological assessment of primary collateral cross-sections (Figure 8A) 
demonstrated similar morphology as was observed in the Chapters I and II; specifically, 
increased intimal cell number without neointimal formation and apparently increased 
vascular wall thickness at 14 days post-ligation, despite the observed impairment in 
luminal expansion.  Figure 8B depicts the average intimal cell number of collateral and 
control arteries.  While there was a significant increase in the number of intimal cells in 
the collaterals versus the controls in both young and old mice (14±1.4 vs. 4.8±0.4 in 
young and 14±1.6 vs. 4.8±0.5 in old, P≤0.001), there was not a significant difference 
between age groups (P = 0.837).  This data is consistent with our previous work in the 
aged rat mesentery (145) and suggests that the age-related impairment in collateral 
growth is similar between different vascular beds in different species.   
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 Discussion: 
 We hypothesized that: there would be an age-related impairment of collateral 
growth in the mouse hindlimb, the injection of young BMCs into aged mice would 
enhance hindlimb collateral growth, ROS balance would be associated with the age-
related impairment of collateral growth, and that this impaired collateral growth would be 
characteristically similar to the age-related impairment of collateral growth in the rat 
mesentery.  The most significant findings of the current study are: 1) verification of a 
transient perfusion and collateral growth impairment in the aged mice at 14 days post-
ligation that was attenuated by 28 days post-ligation (Figures 1, 5, and 6); 2) in contrast 
to studies in younger mice, bone marrow cell (BMC) injection did not enhance limb 
perfusion or collateral growth (Figures 2 and 3, and Table 1); 3) if the impairment in 
collateral growth observed with aging is due to altered BMC function, the problem is not 
related to circulating BMC number (Figure 7); 4) antioxidant therapy showed potential 
for alleviating the impairment in hindlimb perfusion exhibited by aged mice after arterial 
occlusion but had no effect on collateral growth (Figure 4 and Table 1); and 5) the 
characteristics of increased intimal cell number, without neointimal formation, and 
increased vascular wall thickness upon induction of collateral growth are preserved 
despite the impairment in luminal expansion observed in the aged mice at 14 days post-
ligation (Figure 8), consistent with our previous findings in the aged rat mesentery and 
suggesting that the age-related impairment in collateral growth is similar between 
different vascular beds in different species (145).  If the observed increase in intimal cell 
number is taken as a functional assessment, then this data also suggests the endothelial 
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 cells (and/or the EPCs) retain some of their functional capacity in the context of 
advancing age. 
 The current study verifies our previous finding of an age-related impairment in 
the luminal expansion of collateral arteries in the rat mesentery (145), and extends this 
finding to include the mouse hindlimb vasculature (Figure 6).  Our findings are also 
consistent with those of Brownlee and Langille as well as Miyashiro et al. (10, 90) who 
found a decrease in flow-mediated arterial diameter expansion with advancing age.  It has 
been shown that angioscores derived from collateral vessel density in angiograms does 
not necessarily correlate with collateral flow and does not reflect tissue perfusion as 
assessed by microsphere techniques (50).  Thus, by means of a much more direct 
assessment of primary collateral arteries, the current study verifies and extends the 
findings of Rivard et al., who used only an angioscore in rabbits and capillary density 
measurements in mice to demonstrate an age related impairment in collateral growth and 
angiogenesis (106). 
 Our results of an inability of BMC injection therapy to enhance collateral growth 
(Table 1) are in contrast to those of Capoccia et al. (18), despite using the same BMC 
subfraction for our injections.  One explanation is that the vasculature of the young mice 
used in their study may have been receptive to the increased number of BMCs injected, 
while the vasculature of the aged animal may not have been as receptive to injected 
BMCs.  Further studies in aged mice are needed to verify this possibility.  Another 
important difference between the two studies is that Capoccia et al. (18) focused 
primarily on angiogenesis, assessing hindlimb perfusion with LDPI and capillary density 
as the endpoints, while the current study is focused primarily on growth of pre-existing 
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 collateral arteries.  Lastly, there could be a stimulus effect difference between our study 
and that of Capoccia et al. as they utilized a much more severe femoral arterial ligation 
model (with ligation and excision of both the femoral artery and vein down to the 
saphenous artery and vein) than was used in the current study (18).  The more severe 
model used by Capoccia et al. may have resulted in the elimination of arterial and venous 
collaterals that would have remained present in the current study and, thus, microvascular 
growth may be more important when the surgical model utilized is more severe.  In 
addition, Shepherd (124) has shown simultaneous arterial and venous occlusion in 
humans has a detrimental effect on collateral growth, most likely due to increased venous 
pressure.  This would be consistent with the findings of our earlier study that showed 
decreasing hindlimb perfusion with increasing model severity in young C57BL/6 mice 
(Chapter II). 
 One limitation of the current study is that we observed a large degree of inter-
animal variation within treatment groups, especially in the LDPI measurements.  Indeed, 
Figure 5 suggests either a very low degree of reproducibility between LDPI 
measurements or a very high degree of variation between animals purchased from the 
same supplier but ordered several months apart.  Shireman (128) pointed out that several 
other previously published reports experienced considerable variation in LDPI.  Possible 
causes of this LDPI variability include: 1) LDPI is not sensitive enough to detect small 
differences in perfusion because LDPI is based more on the number of red blood cells 
moving through a given tissue region of interest rather than on direct measurement of 
blood flow, 2) LDPI has a penetration depth of only 1 mm which is not deep enough to 
reach the collateral vessels providing the primary bypass for femoral arterial occlusion, 
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 and 3) LDPI is very temperature sensitive and can be greatly effected by the 
vasoconstriction that occurs in the mouse extremities upon changes in ambient 
temperature.  In addition, Epstein’s group has demonstrated that interanimal variability 
can greatly affect the outcome of a study: when all animals were grouped together a 
significant difference was observed in LDPI between those that were treated with 
mesenchymal stem cells and those that were not; however, when the animals were 
subdivided into different groups based on their recovery during the first 24 hours after 
surgery, the significant difference between treatment groups disappeared (164).   
 Another limitation in the current study is that the observed LPDI-measured 
hindlimb perfusion does not always agree with the observed collateral development.  For 
example, Table 1 demonstrates that collateral growth in aged mice at 28 days is 
equivalent between those injected with BMCs/PBS at Day 14 or treated with apocynin 
and those left untreated.  However, if LDPI measured hindlimb perfusion is truly 
dependant on the size of the primary collaterals, then the primary collaterals observed in 
the BMC/apocynin treatment groups should have been the size of those observed in the 
untreated aged mice at 14 days, since the LDPI measured perfusion ratios of the treated 
groups (except the PBS treated group) were all statistically similar to the perfusion ratio 
of the untreated aged mice at 14 days post-ligation (Figures 2, 3, 4, and Table 1).  This is 
in contrast to previous studies that have suggested LDPI correlates well with collateral 
development (34, 121).  One possible explanation for this discrepancy is that LDPI was 
used to measure resting flow (while the vasculature is maintaining vasomotor tone), in 
contrast to the diameter measurements which were obtained at maximal dilation of the 
vasculature at the time of sacrifice.  In addition, collateral dependent perfusion was not 
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 directly assessed due to the limited penetration depth of LDPI.  Another possible 
explanation for the discrepancy between studies is that in the initial study by Couffinhal 
et al. the “collateral” development investigated was actually angiogenesis as opposed to 
the enlargement of primary collaterals performed in the current study (34).  Nevertheless, 
the current results, as well as those from the previous study in Chapter II, suggest LDPI 
of the hind paws is not an adequate method of assessing collateral dependant perfusion. 
 A third limitation of the current study relates to the time point of collateral growth 
assessment.  We first verified a collateral growth impairment at day 14, then planned to 
provide a therapy and measure its effectiveness after an additional 14 days.  However, we 
did not discover until additional experiments were completed that the impairment 
observed at day 14 was attenuated by day 28.  Therefore, the most appropriate 
comparison would have been to provide our injections earlier and then to assess collateral 
growth at day 14 when the verified collateral growth impairment was still present.   
 One final limitation to the current study was the questionable effectiveness of the 
apocynin treatment.  Previous studies in our lab with apocynin used a protocol where 
medicated water was replaced every 48 hours.  However, the medicated water in the 
current study was only replaced every 3-4 days, thus its effectiveness is in question.  This 
may be the reason for the initial effectiveness of the therapy on restoring hindlimb 
perfusion in the aged animals at Day 14 that was eventually lost over the course of the 28 
day recovery period.  Therefore, it is these significant limitations that have led to our 
decision not to submit this data for publication, but, rather, to use it as preliminary data 
for a grant submission. 
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  In order to complete this study, the following additional experiments would need 
to be performed: 1) the BMC injection experiments should be repeated with an earlier 
time point of injection and collateral growth assessment at day 14 post-ligation, 2) the 
apocynin experiment should be repeated with collateral growth assessment at day 14 
post-ligation and strict adherence to the previously described dosing protocol, 3) a more 
accurate method of measuring collateral dependant blood flow should be utilized, such as 
the use of properly sized microspheres or chronic flow probes measuring femoral vein 
return flow, and 4) in order to more directly assess the BMC hypothesis, bone marrow 
transplantation studies generating chimeric animals with GFP+/traceable BMCs (Old 
animals with Young bone marrow and Young animals with Old bone marrow, with the 
appropriate controls) should be utilized with the hindlimb ischemia model to directly 
assess the contribution of BMCs to collateral growth.  In addition, assays to determine the 
functionality of the aged bone marrow cells should also be performed.  Lastly, the safety 
and efficacy of a combined cell and antioxidant therapy should be investigated. 
 In conclusion, we believe our study has allowed us to make some significant 
observations, the most important being that bone marrow cell therapy did not enhance the 
growth of primary collaterals in aged mice.  Indeed, numerous studies in animals and 
even humans are currently being conducted to assess the effectiveness of BMC treatment.  
Our data suggests that the problem may be inherent to the vasculature itself and not lie 
with the circulating cells.  In addition, we believe our aged mouse model is more relevant 
to the clinical situation than young animal models and completion of additional studies 
utilizing aged animals would make a significant contribution to the fields of therapeutic 
angio- and arterio-genesis. 
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 Table 1: Collateral Growth in Treated and Untreated Aged Mice 28 Days Post-Ligation 
  UnTx 
BMI-
Yd14 
BMI-
Od14 
PBS-
d14 
BMI-
Yd1 Apocynin
% Increase in 
Collateral 
Vessel 
Diameter: 
99±29 58±12 40±12 49±11 17±5.0* 59±9.3 
 
Table 1: Collateral Growth in Aged Mice Injected with either BM-MNCs or PBS, or Pre-
treated with Apocynin.  Measurement of in situ gracilis artery collateral diameter 
indicated injection of either young or old BM-MNCs at either day 1 or day 14 post-
ligation did not enhance collateral growth in the aged mice at 28 days post-ligation vs. 
untreated aged mice at 28 days post-occlusion.  UnTx = Untreated aged mice allowed to 
recover for 28 days after ligation; BMI-Yd14 = Old animals injected with young BM-
MNCs at day 14, n = 11; BMI-Od14 = Old animals injected with old BM-MNCs at day 
14, n = 9; PBSd14 = Old animals injected with PBS at day 14, n = 8; BMI-Yd1 = Old 
animals injected with young BM-MNCs at day 1, n = 5; Apocynin = Old animals treated 
with apocynin for one week prior to arterial occlusion and throughout the course of the 
recovery period, n = 5.  *P≤0.001 vs. Old Untreated Day 28. 
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 Figure Legends: 
Figure 1: Hindlimb perfusion in young and old mice.  The perfusion of the experimental 
limb is expressed relative to same animal control at days 1, 7, and 14 post-ligation.  
Hindlimb perfusion increased over time from Day 1 through Day 14 post-ligation in both 
young and old mice; however, the perfusion in the old mice was significantly reduced 
compared to that of the young mice.  Young, n = 6-8; Old, n = 33-41.   
 
Figure 2: Hindlimb perfusion after bone marrow mononuclear cell (BM-MNC) injection 
therapy.  Aged mice were intravenously injected 14 days after femoral artery ligation 
with either young or old BM-MNCs, or PBS and allowed to recover an additional 14 days 
(i.e., 28 days after the original occlusion).  Neither aged mice injected with young BM-
MNCs nor old BM-MNCs exhibited a statistically significant increase in hindlimb 
perfusion compared to the pre-injection perfusion measured at Day 14.  BMI-Y = Old 
animals injected with young BM-MNCs, n = 9-10; BMI-O = Old animals injected with 
old BM-MNCs, n = 10; PBS = Old animals injected with PBS, n = 8-9. 
 
Figure 3: Hindlimb perfusion after injection of BM-MNCs at day 1 post-ligation.  Aged 
mice were injected with young BM-MNCs ~24hrs after femoral arterial ligation and 
allowed to recover an additional 27 days (compare to untreated aged animals).  Injection 
of young BM-MNCs at Day1 post-ligation did not significantly increase the perfusion of 
the hindlimb in aged mice compared to untreated aged mice.  BMI-Y = Old animals 
injected with young BM-MNCs, n = 5. 
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 Figure 4: Hindlimb perfusion in aged mice treated with apocynin.  Apocynin therapy was 
initiated 1 week prior to ligation and continued throughout the recovery period.  
Enhanced perfusion in the apocynin treatment group was short-lived as the perfusion 
values returned to levels similar to untreated aged mice by day 21 post-occlusion. 
Apocynin, n = 5-6. 
 
Figure 5: Hindlimb perfusion in two sets of young and old mice.  The second (2nd) group 
of old and young mice did not reproduce the observations from the initial group because 
1) there was no difference in the recovery of hindlimb perfusion between the 2nd young 
and 2nd old mice at all timepoints investigated and 2) both the 2nd old and 2nd young mice 
demonstrated significantly reduced perfusion ratios vs. the initial group of young and old 
mice.  2nd Young, n = 4-5; 2nd Old, n = 4-5. 
 
Figure 6: Percent increase in collateral vessel diameter in young and old mice 14 and 28 
days post-occlusion.  Diameters for young and old mice at days 14 and 28 post-ligation 
were obtained from digital images of the gracilis artery collaterals in the superficial 
adductor compartment of the hindlimb subsequent to vascular casting with Microfil®.  
Aged mice collateral diameters were significantly smaller than young mice at day 14 
post-collusion but were not different by 28 days after surgery.  Young and Old d14, n = 
5; Young d28, n = 5; Old d28, n = 4. 
 
Figure 7: Analysis of total white blood cells (WBCs) by HEMAVET (A) and CD11b+ 
cells by FACS (B).  While there was no difference in the number of total WBCs, there 
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 were significantly more CD11b+ cells in old mice than in the young from before arterial 
ligation through 3 days post-occlusion.  The number of CD11b+ cells in the old mice 
then fell to match the level observed in the young mice. In addition, there were 
significantly more CD11b+ cells in the young mice at Day 14 tan there were in the young 
mice at Day 0.  Young, n = 3; Old, n = 6. 
 
Figure 8: Assessment of intimal cell number in young and old mice.  As demonstrated by 
the micrographs in panel A, the gracilis collateral arteries of aged mice still display some 
of the characteristics of flow-induced outward remodeling observed in young mice: 
increased intimal cell number, no neointima, and increased wall thickness (vs. control, 
compare to Figure 2D in Chapter II).  Quantitation of intimal cell number from the old 
and young mice is presented in panel B.  Young, n = 6; Old, n = 5. 
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 SUMMARY/DISCUSSION OF THESIS WORK AND FUTURE EXPERIMENTS 
Summary/Discussion: 
   There is little consensus in recent literature regarding the adaptations to arterial 
occlusion, even at the most fundamental levels: what is a collateral, what type of vessel 
can become a collateral, what size are those vessels, how large can they grow, what cells 
are involved, what signaling molecules are involved, why is the process inhibited in the 
presence of cardiovascular disease, and is there a way to enhance collateral growth?  
Through the course of the three studies presented here, I was able to address a number of 
these areas. 
 The simplest definition of a collateral is a natural bypass vessel that provides for 
the flow of blood around a site of occlusion and allows for continued perfusion of the 
distal tissues.  The collateral circulation may consist of a readily identifiable vessel 
providing an immediate bypass or it can be a circuitous path through many vessels.  For 
example, one carotid artery can provide collateral flow to the other carotid via the Circle 
of Willis at the base of the brain.  In order to bypass a site of occlusion, a collateral will 
generally have a proximal stem, a midzone comprised of communicating vessels, and 
then a distal re-entrant point that re-establishes the blood flow in the occluded parent 
artery (81).  While this definition of a collateral is amenable to pre-existent vessels of any 
size, recent studies have purported to show that only specific types of vessels within a 
certain initial size range are capable of experiencing exorbitant degrees of enlargement 
and thus developing into collaterals.  These studies suggest that only pre-existent 
arterioles initially <50 μm in diameter enlarge 10-25X and display neointimal formation 
and wall thinning, via a process now known as arteriogenesis, to become collaterals that 
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 compensate for a parent artery occlusion (14).  However, this definition is inconsistent 
with the results of many previous and current studies as numerous groups, our own 
included, have observed small arteries much larger than arterioles contributing to a 
collateral pathway and demonstrating luminal expansion with vascular wall thickening 
and no neointimal formation (i.e., experiencing collateral growth) (24, 25, 31, 53, 81, 
100, 148).  Thus, the question remains which pre-existing vessels are the most relevant in 
regards to the study of collateral growth?  This controversy was the impetus for my first 
study, which was a survey of the collateral growth occurring in response to femoral 
arterial occlusion in pigs, rats, mice, and humans.  In this study, I observed that the major 
collateral vessels that enlarge in response to femoral arterial occlusion in pigs, rats, and 
mice: 1) were anatomically at the level of the small arteries as opposed to arterioles, 2) 
typically enlarged <3X in contrast to 10-25X, 3) may or may not be tortuous, and 4) 
display wall remodeling characteristics similar to large and small arteries experiencing 
flow-mediated outward remodeling (namely, increased intimal cell number without 
neointimal formation, luminal expansion, and increased wall thickness) instead of 
displaying neointimal formation and wall thinning.  While all these characteristics were 
similar between species, we did observe a 10-100X difference in vessel size, wall 
thickness, and distance from inner to outer wall layers between pigs and mice which we 
hypothesize may drastically effect the diffusion of reactive oxygen and nitrogen species 
as well as paracrine factors within the collateral wall. 
 My second study addressed what cells and signaling molecules may be involved 
in the process of collateral growth.  The prevailing paradigm for collateral growth, based 
on the definition of collaterals as enlarging arterioles, suggests that the recruitment of 
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 monocytes/macrophages is essential for the remodeling to occur (158).  However, flow-
mediated vascular remodeling in large and small arteries occurs without the recruitment 
of these cells and some studies suggest that increased shear stress (widely regarded as the 
stimulus initiating collateral growth) is actually anti-inflammatory (27, 141).  Indeed, 
previous studies in our own lab on rat mesenteric artery collateral growth were 
inconsistent with recent studies in regards to macrophage accumulation in collateral 
arteries which have enlarged; immunohistochemically demonstrating macrophage 
accumulation in the adventitia only sporadically.  Several studies have shown that 
macrophages are only present transiently after abrupt occlusion and inflammation is not 
noted with gradual occlusion (138).  Also, the final endpoints of collateral vessel 
diameter enlargement are similar in some studies of suppressed macrophage function 
(67).  Together these studies raise questions about the clinical relevance of macrophages 
in collateral development. 
Other studies have suggested that reactive oxygen species (ROS), and specifically 
those coming from Nox2-NAD(P)H oxidase, are required for the recovery of hindlimb 
perfusion, angiogenesis, and collateral growth subsequent to femoral arterial occlusion 
(140, 151).  One of the most recent studies links Nox2-NAD(P)H oxidase with bone 
marrow derived cells (BMCs), suggesting that the BMCs are the source of the Nox2-
NAD(P)H oxidase involved in the vascular remodeling response (140, 151).  However, 
despite adequate assessment of hindlimb reperfusion and angiogenesis, the study linking 
Nox2-NAD(P)H oxidase with BMCs did not specifically investigate collateral growth.  
Therefore, we specifically addressed the link between BMC Nox2-NAD(P)H oxidase and 
collateral growth using our technique of major collateral identification in combination 
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 with mouse models of impaired Nox2-NAD(P)H oxidase function (Nox-2 and Rac2 
knockout mice).  A Rac family member is required for Nox2-NAD(P)H oxidase 
activation and Rac2 has been shown to bind to and activate Nox2-NAD(P)H oxidase (38, 
72).  Also, Rac2 is exclusively expressed in the BMCs (68, 107).  Thus, Nox2-NAD(P)H 
oxidase should have been impaired in both vascular and bone marrow-derived cells in the 
Nox2-/- while Nox2-NAD(P)H oxidase should have only been impaired in BMCs in the 
Rac2-/-.  In my second study, I observed both Nox2-/- and Rac2-/- mice demonstrating 
the same phenotype upon femoral arterial ligation: 1) impaired hindlimb reperfusion 
assessed via laser Doppler perfusion imaging, 2) impaired preservation of distal tissue 
morphology, and 3) no impairment in primary collateral growth.  Therefore, I conclude 
that Nox2-NAD(P)H oxidase in either endothelial or bone marrow-derived cells is not 
required for collateral growth but is required for recovery of hindlimb perfusion and the 
preservation of distal tissue morphology.  In addition, this study provides further 
evidence that the processes of angiogenesis and collateral growth are mediated by 
different molecules and mechanisms (13, 19). 
 My final study addresses the impairment of collateral growth in the presence of a 
risk factor of cardiovascular disease and the possibility of enhancing collateral growth in 
the presence of advancing age.  This study was undertaken because previous studies 
primarily used young, healthy mice.  In this study I confirmed an impairment in the 
recovery of hindlimb perfusion as well as a delay in the degree of enlargement 
experienced by the primary collateral vessels at 14 days post-ligation in aged wild-type 
mice versus young controls.  Upon verification of this impairment, I then assessed the 
ability of BMC injection or antioxidant treatment to attenuate the impaired collateral 
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 growth.  I observed that neither BMC injection nor antioxidant therapy enhanced 
collateral growth.  While these results are contrary to previous studies with young healthy 
animals, they may more accurately reflect the situation in aging humans.  However, due 
to problems with interanimal variability and questions of the effectiveness of the 
antioxidant treatment, more experiments are needed before firm conclusions can be 
made. 
 
Future Experiments: 
 In order to complete the study on collateral growth impairment with aging, 
additional old animals should be either injected one day post-ligation or treated with 
apocynin (starting one week prior to ligation and then continuing through the recovery 
period) and collateral growth assessed at day 14 when the collateral growth impairment 
was observed (instead of at day 28, when the impairment may no longer be present).  
Bone marrow transplantation studies to generate chimeric animals (Old animals with 
Young bone marrow and Young animals with Old bone marrow, with the appropriate 
controls) with GFP+/traceable BMCs should be utilized with the hindlimb ischemia 
model to directly assess the contribution of BMCs to collateral development.  In addition, 
assays to determine the functionality of the aged bone marrow cells should also be 
performed.  Lastly, combined BMC and antioxidant therapy should be investigated 
because correction of the altered balance of ROS known to be present in aged animals 
may be necessary for injected BMCs to exert a beneficial effect. 
 In order to more directly assess the role of macrophages in collateral 
development, bone marrow transplantation studies should be performed to generate 
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 chimeric animals using an animal model of inducible macrophage impairment, such as 
the macrophage Fas-induced apoptosis (Mafia) transgenic mice (11).  Since we have 
previously shown C57BL/6 (BL6) mice display normal collateral growth upon femoral 
arterial ligation, the first experiment would be to transplant Mafia mouse bone marrow 
into the BL6 mice and verify there is no impairment in collateral growth after 
transplantation.  The next experiment would then be to transplant the Mafia bone marrow 
into the BL6 mice, perform the femoral ligation, systemically deplete the macrophages in 
the transplanted animals using a synthetic dimerizer (AP20187) (11), and then assess 
whether the growth of primary collaterals is impaired. 
 One potential problem with these proposed transplantation studies is the negative 
effect the transplantation procedure (specifically, the lethal irradiation) may have on the 
endothelium of the recipient animal blood vessels.  Indeed, we conducted some 
preliminary transplantation experiments and, while young BL6 animals transplanted with 
young BL6 bone marrow did grow collaterals, their hindlimb perfusion recovery 
measured via laser Doppler was impaired versus young BL6 that did not receive 
transplantation.  Also, when GFP+ animals were investigated, transgenic animals 
expressing GFP would grow collaterals but their hindlimb perfusion recovery was less 
than wild-type.  In addition, wild-type animals transplanted with GFP+ bone marrow had 
reduced hindlimb perfusion recovery and their collaterals did not enlarge as much as 
wild-type un-transplanted controls.  The problems with hindlimb perfusion recovery may 
be related to the variability issues we had with some of our laser Doppler measurements 
and may not be apparent if a more direct measurement of collateral dependant flow was 
utilized.  Indeed, all future studies would benefit from using a more direct measurement 
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 of collateral dependant flow than that obtained via laser Doppler perfusion imaging.  
Nevertheless, the potential issue of irradiation affecting the ability of the endothelial cells 
to stimulate collateral development would need to be addressed if transplantation studies 
were to be utilized. 
 Lastly, continued investigation of collateral growth in both large, healthy animal 
models as well as in large and small animal models of disease are desperately needed to 
advance the field of therapeutic collateral vessel enhancement.  These models are needed 
since the large animal models would anatomically resemble the human vasculature more 
precisely and because animals possessing comorbidities consistent with human 
cardiovascular disease would more closely resemble the state of the aged, diseased 
human vasculature that is in need of collateral growth therapy. 
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